TRAILblazing Strategies for Cancer Treatment

Anna-Laura Kretz 1, Anna Trauzold 2,3, Andreas Hillenbrand 1, Uwe Knippschild 1, Doris Henne-Bruns 1, Silvia von Karstedt 4,5 and Johannes Lemke 1,*

1 Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany; anna-laura.kretz@uni-ulm.de (A.-L.K.); andreas.hillenbrand@uniklinik-ulm.de (A.H.); uwe.knippschild@uniklinik-ulm.de (U.K.); doris.henne-bruns@uniklinik-ulm.de (D.H.-B.)
2 Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany; atrauzold@email.uni-kiel.de
3 Clinic for General Surgery, Visceral, Thoracic, Transplantation and Pediatric Surgery, University Hospital Schleswig-Holstein, 24105 Kiel, Germany
4 Department of Translational Genomics, University Hospital Cologne, Weyertal 115b, 50931 Cologne, Germany; s.vonkarstedt@uni-koeln.de
5 Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann Straße 26, 50931 Cologne, Germany
* Correspondence: johannes.lemke@uniklinik-ulm.de

Received: 11 March 2019; Accepted: 26 March 2019; Published: 30 March 2019

Abstract: In the late 1990s, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF-family, started receiving much attention for its potential in cancer therapy, due to its capacity to induce apoptosis selectively in tumour cells in vivo. TRAIL binds to its membrane-bound death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) inducing the formation of a death-inducing signalling complex (DISC) thereby activating the apoptotic cascade. The ability of TRAIL to also induce apoptosis independently of p53 makes TRAIL a promising anticancer agent, especially in p53-mutated tumour entities. Thus, several so-called TRAIL receptor agonists (TRAs) were developed. Unfortunately, clinical testing of these TRAs did not reveal any significant anticancer activity, presumably due to inherent or acquired TRAIL resistance of most primary tumour cells. Since the potential power of TRAIL-based therapies still lies in TRAIL’s explicit cancer cell-selectivity, a desirable approach going forward for TRAIL-based cancer therapy is the identification of substances that sensitise tumour cells for TRAIL-induced apoptosis while sparing normal cells. Numerous of such TRAIL-sensitising strategies have been identified within the last decades. However, many of these approaches have not been verified in animal models, and therefore potential toxicity of these approaches has not been taken into consideration. Here, we critically summarise and discuss the status quo of TRAIL signalling in cancer cells and strategies to force tumour cells into undergoing apoptosis triggered by TRAIL as a cancer therapeutic approach. Moreover, we provide an overview and outlook on innovative and promising future TRAIL-based therapeutic strategies.

Keywords: TRAIL signalling; TRAIL sensitising; TRAIL-induced apoptosis; TRAIL in cancer

1. Introduction

Pharmacotherapy for cancer uses one or more chemotherapeutic drugs with either a curative aim or to prolong life and manage symptoms. Chemotherapy targets rapidly dividing cells to slow or stop their growth, conversely not distinguishing between transformed and non-transformed cells which leads to the commonly observed strong side effects in most scenarios. The last decade has seen the development and testing of targeted therapies such as small-molecule inhibitors or monoclonal antibodies. The clinical use of a substance with the ability to selectively kill tumour cells while
sparing healthy cells thereby reducing severe side effects is urgently needed in pharmacological cancer therapy. This “silver bullet” against cancer seemed close at hand in 1995 when tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) was introduced \[1,2\] and later shown to selectively induce apoptosis in tumour cells in vivo \[3,4\]. After much testing, this selectivity holds to this day, however, its efficacy to induce significant levels of apoptosis in some resistant cancers will have to be helped through additional means.

2. The TRAIL System

TRAIL is a type II transmembrane protein with apoptosis-inducing capabilities, which belongs to the TNF-superfamily (TNF-SF) \[1,2\]. In humans, apoptosis is induced by binding of TRAIL to the death receptors (DR) TRAIL-R1/DR4 (also called APO-2 or TNFRSF10A) \[5\] and TRAIL-R2/DR5 (TNFRSF10B, TRICK2, KILLER) \[6\]. TRAIL is active as a trimer, analogous to other TNF-SF members, and consequently binds three receptor molecules \[7,8\]. Besides TRAIL-R1 and TRAIL-R2, TRAIL engages TRAIL-R3 (DcR1, TNFRSF10C, TRID, LIT) and TRAIL-R4 (DcR2, DcR2, TNFRSF10D, TRUNDD) also designated as decoy receptors (DcR), and the soluble receptor osteoprotegerin (OPG, TNFRSF11B). These latter three receptors are thought to potentially negatively regulate apoptosis through TRAIL-R1 and -R2 by scavenging TRAIL \[9–14\]. TRAIL-R1 and TRAIL-R2 mediate apoptosis via a cytoplasmic death domain (DD), which is missing in TRAIL-R3 and is truncated in TRAIL-R4 \[6,12,15–17\]. In a physiological setting, the affinity of TRAIL to OPG is notably weaker compared to the membrane-bound receptors suggesting a subordinate role of the soluble receptor in TRAIL signalling \[18,19\]. Noteworthy, when being presented at low concentrations and under physiological conditions, TRAIL favours interaction with TRAIL-R2 \[20\]. Eventually, TRAIL-R2 was presumed as the preferential inducer of apoptosis. Though, this assumption has been debunked since, for instance, in lymphocytic leukaemia and a variety of pancreatic cancer cells, apoptosis is induced via TRAIL-R1 although TRAIL-R2 is present and functioning. Consequently, the precedence for one receptor seems to be tumour entity-dependent \[21–24\].

In mice, only one death-inducing TRAIL-R is expressed, mTRAIL-R (MK) sharing 43% and 49% sequence homology with human TRAIL-R1 and TRAIL-R2, respectively \[25\]. The murine decoy counterparts mDcTRAIL-R1 (TNFRS23) and mDcTRAIL-R2 (TNFRS22) lack a DD and differ widely from the amino acid sequence of human TRAIL-R3 and -R4 \[26\].

Despite a research history of more than 20 years, it is still puzzling why humans have evolved to express two death-inducing TRAIL-Rs \[5,27\]. In addition, TRAIL-R2 is expressed as short and long splice variant with a difference of an additional 29 amino acid stretch present in the extracellular domain of the long TRAIL-R2 isoform. However, a higher incidence of expression of the long isoform is described, whereas the ratio of the variants differs tissue-dependently \[28\].

3. The Apoptotic ‘TRAIL’

The induction of apoptosis can be subdivided into either intrinsic apoptosis, triggered by p53 in response to cellular injuries \[29\] or extrinsic apoptosis induced upon death ligand binding to a death receptor. Caspases orchestrate both apoptosis pathways via cleavage of target proteins (reviewed in \[30–33\]). Conventional chemotherapy triggers intrinsic apoptosis through p53 in response to cellular damage. Nevertheless, many tumour entities contain mutations in p53 leading to its inactivation and failure of chemotherapy. In stark contrast to this, TRAIL-induced apoptosis remains possible in numerous cases despite non-functional p53 \[34–37\]. In Figure 1, the TRAIL-induced apoptotic signalling is illustrated.
Figure 1. TRAIL signalling and sensitisation. Human tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) can bind to four membrane-bound TRAIL receptors (TRAIL-Rs) and one soluble receptor ①. TRAIL-R1 and TRAIL-R2 can trigger apoptotic signals while the other receptors might serve as decoys and regulate apoptosis negatively. Cysteine-rich domains of the receptors are crucial for ligand binding. Following TRAIL binding to TRAIL-R1 or TRAIL-R2, the death-inducing signalling complex (DISC) is assembled ②. In type I cells, the signal of DISC-released caspase-8 is sufficient for activation of further downstream caspases and apoptosis induction ③, whereas the DISC signal is amplified via mitochondria in type II cells ④. Cleaved and thereby truncated Bid (tBid) activates the mitochondria-associated B-cell CLL/lymphoma 2 (Bcl-2)-family members Bcl-2-associated X protein (Bax) and Bcl-2 antagonist or killer (Bak) resulting in mitochondrial outer membrane permeabilisation (MOMP) and finally cytochrome c and second mitochondrial activator of caspases/direct inhibitor of apoptosis-binding protein with low isoelectric point (pI) (SMAC/DIABLO) release. The apoptosome comprising apoptotic protease activating factor-1 (Apaf-1), cytochrome c, and caspase-9, presents the activation platform for caspase-9 which leads eventually to the activation of executioner caspases ⑤. p53 is activated in response to stress signals such as DNA damage and promotes Bcl-2 homology (BH)3-only proteins resulting in MOMP. TRAIL-receptor-interaction can provoke the formation of a second cytosolic complex ⑥, retaining Fas-associated protein with death domain (FADD) and caspase-8 and recruiting receptor-interacting serine/threonine-protein kinase 1 (RIPK1), TNF receptor-associated factor 2 (TRAF2), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) essential modulator (NEMO) [38–40]. TRAF2 recruits cellular inhibitor of apoptosis protein 1/2 (cIAP1/2) which in turn trigger the ubiquitination of RIPK1 and therefore recruitment of linear ubiquitin chain assembly complex (LUBAC) [41]. LUBAC poly-ubiquitinylates
RIPK1. RIPK1 is the stimulus for tyrosine-protein kinase Src and signal transducer and activator of transcription 3 (STAT3) promoting migration and invasion [42]. Complex I and complex II induce NF-κB, p38 mitogen-activated protein kinase (p38 MAPK), c-JUN N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) pathways. LUBAC is present in both complexes, responsible for caspase-8 activation and recruitment of the inhibitor of κB (IκB) kinase (IKK) complex, and consequently activation of NF-κB [41]. In case of blocked caspase-8, the necrosome is formed by the interaction of RIPK1 and RIPK3. Independently of FADD and complex I and II, the membrane-proximal domain (MPD) of TRAIL-R2 can activate Ras-related C3 botulinum toxin substrate 1 (Rac1) to promote migration and invasion [43]. TRAIL-R2 can also occur in the nucleus where it interacts with ribonucleoprotein complexes involved in the maturation of microRNAs (miRNAs) of the let-7 family. These miRNAs interact with and constrain mRNAs of several regulators of mitogenic pathways such as Ras and c-Myc thereby encouraging proliferation of tumour cells [44]. Further abbreviations: glycosylphosphatidylinositol (GPI), osteoprotegerin (OPG), death domain (DD).

3.1. TRAIL-Induced Extrinsic Apoptosis

TRAIL binding to TRAIL-R1 and TRAIL-R2, respectively, initiates extrinsic apoptosis through receptor trimerisation and assembly of the death-inducing signalling complex (DISC) platform at their cytoplasmatic domains [45–47]. Caspase-8 and cellular FLICE-like IL-1β-converting enzyme-inhibitory protein long/short (c-FLIP\(_{L/S}\)), are recruited to TRAIL-Rs via a homotypic interaction between the death domains (DDs) within the receptor and the adapter molecule Fas-associated death domain (FADD) [48,49]. The exact stoichiometric composition of the DISC unveiled three TRAIL-Rs recruiting one FADD molecule, its death effector domain (DED) in turn recruiting DED-only proteins (procaspase-8/procaspase-10 molecules or isoforms of c-FLIP [46,49,50]. The fact that procaspase-8 contains two DEDs has led to modelling of caspase-8 recruitment as a growing chain wherein merely the first procaspase-8 molecule directly binds to FADD [49,50]. Eventually, DISC formation allows procaspase-8/-10 dimerisation, its activation, and further activation of downstream caspases [13,48–50].

The caspase-8 homolog c-FLIP fulfils a particular function in regulating caspase-8 activity at the DISC [50–55]. Depending on the isoform, c-FLIP can act on caspase-8 in an antiapoptotic or proapoptotic manner [54]. An early, simpler concept of a negative regulation was based on the observation that c-FLIP could compete with caspase-8 for FADD binding [55–57]. Isoform-wise, c-FLIP long (c-FLIP\(_L\)) is highly homologous to procaspase-8, but lacks a catalytic cysteine residue in the active site and therefore proteolytic activity. c-FLIP short (c-FLIP\(_S\)) represents a shortened variant containing only tandem DEDs [58,59]. c-FLIP\(_S\) seems to perform anti-apoptotically, whereas c-FLIP\(_L\)’s regulatory function is more complex [60]. Both splice variants, c-FLIP\(_S\) and c-FLIP\(_L\), can inhibit the activation of caspase-8 at the DISC when overexpressed [58,59,61]. Conversely, in an alternative scenario, c-FLIP\(_L\), and procaspase-8 can form an active heterodimer, which has been shown to promote apoptosis induction, but also to inhibit RIPK3-dependent necroptosis [62–65]. Recently, the prior model of procaspase-8 and c-FLIP competing for FADD banding has been revised at it was shown in vitro that c-FLIP recruitment to the DISC follows sequentially after an interaction of procaspase-8 and FADD has been established [54].

3.2. TRAIL-Induced Cross-Signalling to Mitochondria

Soon after the discovery of TRAIL/TRAIL-Rs, it became evident that not all cells follow a similar linear pathway of TRAIL-induced extrinsic apoptosis. Some cells’ sensitivity depended on the ratio and expression levels of mitochondria-associated B-cell CLL/lymphoma 2 (Bcl-2) family proteins [66,67].

We now know that two cell types can be distinguished regarding their requirement to cross-signal to the mitochondrial apoptotic machinery [68]. In type I cells, DISC activation is sufficient to effectively trigger the full caspase cascade. Conversely, in type II cells, DISC activation does not result in efficient downstream caspase-3 activation and, hence, requires mitochondrial outer membrane permeabilisation.
(MOMP) to release the second mitochondrial activator of caspases/direct inhibitor of apoptosis-binding protein with low isoelectric point (pI) (SMAC/DIABLO) for counteracting protein X-linked inhibitor of apoptosis protein (XIAP) \[68,69\]. Additionally, the level of XIAP is decisive in whether a cell undergoes type I or type II apoptosis \[69\]. MOMP is enabled by caspase-8-mediated cleavage of the Bcl-2 homology (BH)3-only protein (Bid) generating truncated Bid (tBid) \[73\], which translocates to the mitochondria and eventually activates the mitochondrial cascade (intrinsic apoptosis) by generating an oligomerisation \[74,75\] of Bcl-2-associated X protein (Bax) and Bcl-2 antagonist or killer (Bak) \[73,76\]. These Bcl-2 proteins permeabilise the mitochondrial outer membrane (MOM) leading to the release of cytochrome c into the cytosol. The cytochrome c concentration in the cytosol stimulates protease activating factor-1 (Apaf-1), which in turn mediates the assemblage of the apoptosome, the intracellular activation platform for procaspase-9. Active procaspase-9 promotes further activation of caspases-3, -6, and -7, which eventually execute apoptosis \[33,77\].

3.3. Checkpoints for TRAIL-Induced Apoptosis

Maintenance of the balance between death receptor-induced cell death and survival in non-malignant cells is achieved by numerous manifold control instruments \[78\], although not yet fully described, an interesting recent publication has revealed that many adult tissues downregulate pro-apoptotic proteins after birth, making them highly resistant against apoptotic stimuli \[79\]. The expression of decoy receptors can prevent apoptosis induction \[80–82\]. At the DISC, the inhibitor of caspase-8, c-FLIP, is upregulated following the induction of nuclear factor kappa light chain enhancer of activated B cells (NF-κB), thereby blocking apoptosis \[83,84\]. In type II cells, MOMP can be prevented when Bax and Bak are converted to their inactive form by binding of Bcl-2, Bcl-xL, or induced myeloid leukaemia cell differentiation protein (Mcl-1) \[84\]. The release of cytochrome c upon MOMP is accompanied by SMAC/DIABLO \[33,85,86\]. SMAC/DIABLO binds and inactivates XIAP enabling effective activation of the effector caspase cascade and execution of cell death \[66,84\].

4. On the TRAIL for Targeted Cancer Therapy

In 1999, two independent groups demonstrated tumour regression in xenografts after systemic treatment with recombinant variants of human TRAIL (rhTRAIL) \[3,4\]. The consistent tumour cell-selective, apoptosis-inducing capabilities of TRAIL in preclinical research encouraged the development of clinical TRAIL-R agonists (TRAs). Two sets of TRAs used for clinical testing can be distinguished: (i) recombinant forms of human TRAIL and (ii) agonistic antibodies targeting TRAIL-R1 or TRAIL-R2 \[14,87,88\]. However, in order to achieve higher killing activity and considering the tissue-dependent preference of one specific TRAIL-R to induce apoptosis, an active agent targeting both apoptosis-inducing TRAIL-Rs is preferable \[21–24\].

4.1. TRAs in Clinical Studies—Can Failure Still Lead to Success?

First hopes in targeting a death receptor for cancer therapy became disillusioning when fulminant toxicity occurred in clinical trials of phase I and phase II testing recombinant TNF-α \[89,90\]. The TNF-SF system gained attention again when non-toxic and tumour cell-selective killing could be observed using TRAIL instead. Currently, only one recombinant form of human TRAIL, dulanermin (APO2L.0, AMG-951) (Figure 2), has reached clinical trials. The substance is untagged and comprises amino acids 114–281 of the extracellular portion of TRAIL and binds both death-inducing TRAIL-Rs \[4\]. Clinical phase I studies established tolerability and safety of TRAIL without dose-limiting toxicity (DLT), either as single-agent or in combination with conventional chemotherapeutic drugs for advanced non-small-cell lung cancer (NSCLC), non-Hodgkin lymphoma, colorectal cancer, advanced cancers, and B-cell lymphoma \[91–97\]. A maximum tolerated dose (MTD) could not be reached in the dose escalation study \[96\]. Nonetheless, the antitumor effects from preclinical models could not be confirmed in a phase II study paired with paclitaxel, carboplatin, and bevacizumab in advanced...
NSCLC [98]. The efficacy of dulanermin was eminently limited by its serum half-life of only 30–60 min restricting its ability to reach and kill cancer cells [99], and to achieve a steady-state concentration without continuous parenteral administration. Due to the weak response to dulanermin, it was not practicable to find biomarkers to predict the activity of the substance and patients’ response [100]. Following this initial failure, in 2017 the results of a phase III study of dulanermin combined with the semi-synthetic vinca-alkaloid vinorelbine [101] and the platinum-based cisplatin [102] for patients with NSCLC have been published. The objective response rate (ORR) was 46.78% in the treated group versus 30.00% in the placebo group. The progression-free survival (PFS) could be doubled in the treatment arm, however, a significant effect on the overall survival (OS) was not detectable [103]. It is thus doubtful, whether the response of the treatment was generated from the combination of dulanermin with the cytostatics or merely from the established drugs alone.

Agonistic TRAIL-R-specific antibodies also entered clinical trials. These are mapatumumab targeting TRAIL-R1 and conatumumab, lexatumumab, drozitumab, and LBY-135 which are all directed against TRAIL-R2 [87]. An advantage of these antibodies is their prolonged half-life in serum, usually prolonged from days to weeks. Just like dulanermin, these agonistic antibodies achieved favourable results in preclinical experiments [104,105] and were well tolerable and safe in first launched in-human studies [96,106–111]. Despite improved half-lives, their anticancer activities have been very limited.

Given its positive preclinical performance, TRAIL has been downgraded from a ‘non-plus ultra’ agent for cancer treatment to a ‘plus ultra’ agent. Noteworthy, anti-TRAIL-R antibodies have been primarily evaluated in solid tumours. Blood perfusion of solid tumours is significantly restricted to provide a hypoxic, pro-tumorigenic surrounding. Poor perfusion within solid tumours might have hampered TRAIL’s efficacy in these entities [112]. Moreover, solid tumours are often protected by a complex immune- and non-immune microenvironment [113]. Another shortcoming of TRAIL-R targeting antibodies might lie in their Y-structure providing only two TRAIL-R-binding epitopes whereas efficient TRAIL-R-triggering requires cross-linking of receptor trimers [114,115]. Although, TRAIL-R-targeting antibodies failed in most patients, a small percentage responded to monotherapy. Therefore, predictive biomarkers would offer the potential to identify patients who might benefit. In 2007, a first such biomarker was published. The study found polypeptide N-acetylgalactosaminyltransferase 14 (GALNT14) expression to correlate with the cells’ sensitivity to TRAIL [116]. However, this biomarker of response could not be confirmed in patients, so far.

Nevertheless, high demand for targeting strategies while sparing healthy cells led to further development of TRAIL-R-targeting antibodies. TAS266 (Figure 2), a TRAIL-R2-specific, tetravalent nanobody was evaluated in clinical studies [117]. The small size of nanobodies is advantageous for distribution and tumour targeting. Moreover, nanobodies are highly stable, soluble, and specific and can be easily cloned [118]. TAS266 comprises four humanised high-affinity heavy chain domain (VHH) antibody fragments which enable clustering of four TRAIL-R2s [117]. The substance is an example for the pitfalls which come with excessively potent molecules since fulminant liver toxicity obliged the termination of the phase I clinical trial. Although the underlying mechanism causing the toxicity is not fully understood, the high potency of the molecule, potential immunogenicity and amplified TRAIL-R2 expression on liver cells may have caused an increased clustering of the receptors. In three patients suffering from the DLT pre-existing antibodies were detected able to bind to TAS266 [119].
Figure 2. Highly potent TRAIL receptor agonists (TRAs) and combinatorial approaches. Schematic illustration of native tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) and potent TRAs evaluated in clinical studies or with promising results in preclinical experiments and their combination with anticancer approaches: native membrane-bound TRAIL is a protein of 281 amino acids (aa) comprising a cytoplasmic domain (aa 1–17), a transmembrane domain (aa 18–38), and an extracellular domain (aa 39–281). The receptor-binding domain (aa 114–281) is located in the extracellular portion [1] which is cleaved from the cell surface to form bell-shaped homo-trimers. Recombinant human TRAIL/Apo2L (dulanermin) is based on the amino acids 114–281 of the extracellular portion of TRAIL [4]. The patients’ benefit in clinical trials was merely marginal even combined with chemotherapeutic regimens such as FOLFIRI (folinic acid, fluorouracil, irinotecan) [93,94]. Tags at the N-terminus of the extracellular domain of TRAIL such as FLAG and poly-histidine (His) aid purification of the ligand and leucine zipper (LZ) and isoleucine zipper (iz) stabilize the trimers [3,120]. Circularly permuted TRAIL (CPT) consists of the N-terminal amino acids 121–135 linked to the C-terminal amino acids 135–281 of TRAIL via a flexible linker [121]. To achieve the fragment crystallizable region (Fc)-TRAIL fusion protein, the Fc portion of human immunoglobulin G1 (IgG1) was fused to the N-terminus of human TRAIL (aa 95 to 281) [122]. Single-chain TRAIL (scTRAIL) is assembled by 3 extracellular domains of TRAIL that are covalently connected by 2 short peptide sequences [123]. APG350 was developed by the fusion of scTRAIL and the Fc-part of a human IgG1 leading to six receptor binding sites per drug molecule [124]. TAS266 comprises four humanised high-affinity heavy chain domain (VHH) antibody fragments which enable clustering of four TRAIL-R2s [117]. The substance caused severe hepatotoxicity in clinical phase I studies. The tetravalent fibroblast-activation protein (FAP)-TRAIL-R2 antibody RG7386, targets cancer-associated fibroblasts in the tumour stroma and TRAIL-R2 on tumour cells simultaneously thereby inducing higher-order clustering and apoptosis induction in vitro and animal models [125].
Circularly permuted TRAIL (CPT) (Figure 2) is a novel form of recombinant human Apo2L/TRAIL with ongoing clinical evaluation for multiple myeloma (MM) and other hematologic cancers. It consists of the N-terminal amino acids 121–135 linked to the C-terminal amino acids 135–281 of TRAIL via a flexible linker. CPT’s pharmacokinetic is superior to wild-type TRAIL due to an enhanced stability and half-life [121]. In a single dose-escalation study adverse effects such as fever, fatigue, leucopenia, and vomiting remained below 10% incidence, and no immune responses were traceable [126]. To further evaluate the safety and efficacy of CPT as single agent, a phase II open-label study has been initiated. The monotherapy was well tolerated with 20–30% partially- or better-responding patients. No DLT and MTD could be observed [127]. A further dose-finding phase II study enrolled thalidomide-resistant relapsed refractory multiple myeloma (RRMM) patients and investigated the combination of CPT with the MM-approved drug thalidomide. The drug has been initially distributed under the trade name Contergan® (Chemie-Grünenthal, Aachen, Germany) as sleeping pill, known from the Contergan disaster [128]. The ORR was 22%, however, treatment-related adverse effects (TRAE) occurred more often in the combinatorial treatment versus the single-agent treatment. The rate of higher-grade adverse effects had been certainly lower compared to the treatment with first-line therapy for MM such as bortezomib [129] demonstrating a comparatively low toxicity of the treatment regimen. An antitumour effect could be denoted, while no DLT occurred [130]. A phase II study for RRMM was conducted to compare the safety and efficacy of CPT plus thalidomide combined with dexamethasone (CPT + TD arm) and thalidomide plus dexamethasone (TD arm) [131]. The trial wanted to harness the antiproliferative effect of the glucocorticoid dexamethasone on melanoma cells [132]. The ORR of the CPT + TD arm was 38.3% compared to the ORR of the TD arm with 25%. Occurring TRAEs were in large part of the lower grades, whereas around 20% of patients suffered from severe side effects [131]. Currently, CPT presents the exception considering the antitumour potential amongst the TRAs. These findings provided the rationale for prospective confirmatory studies.

ABBV-621 is designed for higher-order clustering of TRAIL-Rs by fusing an immunoglobulin G1 (IgG1)-fragment crystallizable region (Fc) portion to a single chain trimer of TRAIL subunits. In this way, six TRAIL-R binding sites are available upon dimerization of Fc portions. As with other TRAs, the preclinical data were promising. Apoptosis-inducing efficiency was observed in hematologic malignancies alone and in combination with the sensitisers navitoclax and venetoclax (see Section 5.4. BH3 and SMAC mimetics plus TRAIL) [133]. Currently, pre-treated patients are recruited for a dose-escalation study in solid tumours and hematologic malignancies using ABBV-621 (ClinicalTrials.gov Identifier: NCT03082209). The results are expected in February 2021.

Although CPT is the exception amongst TRAs boasting attributable anti-tumour action in clinical settings, a notable patient number showed no responses to the treatment. The main reason for the disappointing outcome of the majority of TRAs can be found in the inherent insensitivity of tumour cells to TRAIL monotherapy or acquired resistance [134–136]. To overcome this resistance, more profound understanding of the underlying mechanisms is vitally important.

4.2. TRAIL Resistance Mechanisms in Cancer

One hallmark of cancer is an intrinsic or acquired resistance to apoptotic signals [137]. The TRAIL-induced apoptosis pathway provides manifold steps at which sensitivity can be modified starting with regulation of TRAIL-R levels and stretching all the way to mitochondrial anti-apoptotic proteins (Figure 1) [138–140]. While the big picture of TRAIL resistance is still not completely understood, numerous details and steps of the mechanism have been revealed [13,14,87].

4.2.1. TRAIL Receptors

At the receptor level, mutations in TRAIL-R1 and TRAIL-R2 [141–143], and expression of the decoy receptors TRAIL-R3 and TRAIL-R4 lacking the functional intracellular DD may play a regulatory role in TRAIL-induced apoptosis [9,16,82]. DcRs, particularly TRAIL-R4, might compete for TRAIL binding or may disrupt trimerisation of the death-inducing receptors -R1 and -R2 [9,144,145] when co-expressed.
on the same cell. Indeed, TRAIL-R4 was shown to directly interact with the death-inducing receptors directly thereby disrupting efficient DISC formation [82,145], and to signal alternative, tumour-promoting pathways such as NF-κB. Intriguingly, DcRs expressed by stromal cells have been demonstrated to negatively influence TRAIL sensitivity of tumour cells [146]. There is mounting evidence that in contrast with its name, TRAIL seems to generate versatile effects, while enhanced tumour progression and metastasis could be observed upon treatment with exogenous TRAIL and activation of alternative pathways [147]. Moreover, in Kirsten rat sarcoma (KRAS)-mutated cancer upregulated TRAIL-R2 and endogenous TRAIL act in a tumour-supportive manner [43], a concept which does not seem to be limited to KRAS-mutated cancers and also engages tumour-favourable polarisation of immune cells [148].

Post-translational modifications of TRAIL-Rs have gained increasing interest over the last couple of years [149]. O-Glycosylation of TRAIL-R2 was found to control the cells’ sensitivity to TRAIL (described previously as a possible biomarker (see Section 4.1 above TRAs in Clinical Studies—Can Failure still lead to success?). A whole genome-profiling approach identified a correlation of increased GALNT14 and TRAIL resistance. Cells could be sensitised to apoptosis when GALNT14 was silenced [116]. In line with the idea that posttranslational modifications of the receptors have a considerable effect on TRAIL binding and killing, N-glycosylation of TRAIL-R1 increased its apoptotic efficacy [150,151].

Besides their membrane localisation, TRAIL-Rs have been observed also in intracellular compartments and in the nucleus [152,153]. The cellular localisation of TRAIL-Rs seems to play a growing role in TRAIL non-apoptotic signalling. Recent experiments revealed a correlation between increased levels of nuclear TRAIL-R2 and shortened patient survival, indicating a tumour-promoting role of the nuclear variant [44].

4.2.2. The DISC

At the DISC level, FADD was shown to be indispensable for TRAIL-triggered apoptosis and loss of function led to resistance to TRAIL [48,154]. c-FLIP overexpression was detected in TRAIL-resistant cancer [155,156]. This antiapoptotic regulator and caspase-8 seem to be critical factors and unique molecules in death-receptor apoptosis signalling [48,55,139,157–159]. Recent discoveries identified a novel deubiquitylase of c-FLIPL, ubiquitin-specific peptidase 8 (USP8), directly interacting with the long isoform leading to its stabilisation and thereby inhibition of DR-induced apoptosis. Interestingly, increased levels of USP8 were found in melanoma and cervical cancer [160]. Changes in c-FLIP [155,161,162] and caspase-8 ratio [163] can trigger cell death-independent cellular responses via a cytosolic signalling complex termed complex II [164]. This complex II includes, besides the DISC components FADD and caspase-8, receptor-interacting protein kinase (RIPK1), TNF receptor-associated factor-2 (TRAF2) and NF-κB essential modifier (NEMO)/inhibitor of κB (IκB) kinase (IKK) [38–40]. TRAF2 recruits cellular inhibitor of apoptosis protein 1/2 (cIAP1/2) that in turn promote the ubiquitination of RIPK1 [165] thereby presenting the recruitment platform for linear ubiquitin chain assembly complex (LUBAC) [41]. LUBAC adds linear poly-ubiquitin chains to RIPK1 and completes tasks in complex I and complex II, enabling caspase-8 cleavage and IKK complex assembly, and accordingly activation of NF-κB [27,35,41,166–172]. Triggering the NF-κB pathway is one example of TRAIL’s non-canonical signalling routes occurring at the DISC level and conveying TRAIL resistance (Figure 1). Moreover, activation of mitogen-activated protein kinase (MAPK) [173,174] and tyrosine kinase Src and phosphoinositide 3-kinase (PI3K) pathways [175] through this complex II have been described [14].

4.2.3. Bcl-2 Family

TRAIL resistance can also be attributed to expression patterns of the Bcl-2 family [13,87]: If cells undergo type II extrinsic apoptosis, death signals need the amplification via the mitochondrial pathway. Here, the ratio of the proapoptotic proteins Bax and Bak [176] and their antiapoptotic antagonists
Bcl-2, Bcl-xL, and Mcl-1 \([177–182]\) govern cell fate \([78]\). The mitochondrial release of SMAC/DIABLO ensuring activation of effector caspases, for example, is inhibited by Bcl-2 overexpression \([183]\).

4.2.4. IAPs

As indicated by their name, inhibitors of apoptosis proteins (IAPs) can block programmed cell death \([184]\) and mediate TRAIL resistance \([180,181,185–187]\) by regulating effector caspase activity such as caspase-3 or by inhibiting caspase-9 and apoptosome activity. An upregulation of IAPs has been described as a common feature of cancer \([188–190]\). The human IAP family comprises eight members so far, which have at least one baculovirus IAP repeat (BIR) domain in common: neuronal apoptosis inhibitory protein (NAIP; BIRC1), cIAP1, cIAP2 (BIRC2 and BIRC3), XIAP (BIRC4), survivin (BIRC5), BRUCE (Apolon; BIRC6), livin (BIRC7), and testis-specific IAP (Ts-IAP; BIRC8). Caspases of the apoptotic cascade are inhibited by XIAP, cIAP1, c-IAP2, and survivin \([191,192]\).

4.2.5. Autophagy—The Self-Consuming TRAIL

Besides its apoptosis-inducing capabilities, TRAIL is associated with autophagy. Autophagy (or autophagocytosis) is an essential cellular degradation mechanism to remove damaged or redundant proteins and cell organelles \([193]\). Since the 1950s, the mechanism has enthralled cell scientists. The cell biologist Yoshinori Ohsumi was rewarded with the 2016 Nobel Prize in Physiology or Medicine for the early description of the autophagy machinery \([194]\), while other aspects are still obscure. The mechanism is involved in growth regulation and ageing processes and a diversity of other cellular functions such as differentiation and pathogen defence \([195–197]\). During periods of increased nutritional stress, the cellular components are recycled to maintain cell survival. Apoptosis and autophagy’s elements have various points of contact indicating the multifaceted cross-talk between the pathways. Usually, autophagy blocks apoptosis induction, and caspase activation in the apoptotic cascade shuts off autophagy signalling. One of the crucial controllers of autophagy is the mechanistic target of rapamycin (mTOR) kinase controlled by starvation, growth factors, and cellular stressors \([197,198]\). Upon DNA damage, p53 mediates the activation of AMP-activated protein kinase (AMPK) and thereby the blockage of mTOR and autophagy \([199]\). However, collected data over the last decade describes that p53 can also act in an autophagy-activating manner \([200,201]\). Beclin 1 (autophagy-related gene 6, ATG6) holds a vital role in the surveillance of autophagic actions \([202,203]\) and the crosstalk between apoptosis and autophagy \([198]\). The Bcl-2 family members Bcl-2, Bcl-xL, and Mcl-1 are regulators of Beclin 1 by directly interacting with its BH3 domain. Noteworthy, the underlying mechanism of how these proteins either inhibit or stimulate autophagy and apoptosis is poorly understood \([204]\).

Apoptosis and autophagy are both stimulated in response to metabolic stressors, however, in tumour cells, a different picture emerges, and the dialogue between autophagy and apoptosis is disrupted \([193,205,206]\). Generally, the nature of autophagy in cancer is bivalent, most likely describable as dynamic, demonstrated by either tumour-supportive or -suppressive actions \([206–208]\). Due to this interplay of autophagy and apoptosis, studies have been focused on the link between TRAIL resistance and autophagy. The connection between the mechanisms has become tangible when TRAIL has been shown to induce both, apoptosis and autophagy, in a series of cancer cell lines \([209–211]\). For cytoprotective TRAIL-induced autophagy, the activation of TRAF2- and RIPK1-mediated MAPK8/c-Jun N-terminal kinases (JNK) signalling \([212]\) and AMPK signalling \([213]\) was reported. In a nutshell, these results suggest that several pathways and regulators work together in a concerted manner to mediate TRAIL-induced apoptosis and autophagy. There are accumulating results in recent years identifying further regulators which maintain the crosslinking of apoptosis and autophagy. Notable, caspase-9 as such regulator facilitates the early events leading to autophagosome formation by complexing with ATG proteins thereby suppressing the apoptotic character of the caspase \([214]\).
Autophagy controls the timing and efficiency of TRAIL-induced MOMP by the level of autophagy-releasing p53 upregulated modulator of apoptosis (PUMA, also known as Bcl-2-binding component 3) [215], a proapoptotic BH3-only Bcl-2 family member and downstream target of p53. MOMP is inefficient in cells with low PUMA levels, and some of these cells have been observed to recover and divide again whereas high PUMA levels led to MOMP quickly followed by apoptosis [216]. Most solid tumours exhibit areas permanently or transiently under hypoxic conditions resulting from abnormal vascularisation and blood flow [217]. The hypoxia intensifies mitochondrial autophagy in colorectal cancer cells. This loss of the cell organelles leads eventually to the scarcity of mitochondria-derived pro-apoptotic molecules such as SMAC thereby disrupting the transmission of TRAIL-mediated apoptotic signals in type II cells [218].

Recently, the accumulation of autophagic organelles in TRAIL-resistant cancer cell lines has been described. It was proven that this accretion led to TRAIL resistance in breast cancer cells that was accompanied by decreased surface expression of TRAIL-R1 and TRAIL-R2 [219]. The influence of autophagy on TRAIL-induced apoptosis in metastasis was just investigated by use of in vitro circulating tumour cells (CTCs) models for breast cancer which developed resistance to TRAIL with transition to a non-adherent state. This resistance was connected with downregulated surface levels of TRAIL-R2. The CTCs showed a fast autophagic flux detectable by an increase of autophagosome organelles where TRAIL-R2 was degraded [220]. The data obtained reveal a potential mechanism of how autophagy contributes to bypass TRAIL-induced apoptosis in CTCs.

Taken together, TRAIL-induced apoptosis and autophagy are controlled by a plethora of pathways and often shared regulators that are not fully explored. This crosstalk gains in importance, and insights into this highly complex network in the period ahead contributes to novel treatment approaches in TRAIL-related cancer therapy including autophagy inhibitors such as beclin 1 inhibitors or inhibitors of PI3K.

4.2.6. Fractional Killing and Microenvironment

TRAIL resistance can occur during treatment cycles when only a fraction of cancer cells die due to cell cycle-imposed variations in pro- and anti-apoptotic protein levels. This enigmatic phenomenon has a non-genetic origin termed “fractional killing” [221]. A hypothesis for fractional killing by TRAIL is a caspase activation threshold determined by caspase inhibitory protein levels in cells at the time of TRAIL stimulation [222]. Eventually over time, monotherapy with TRAIL may select for survival of a resistant cell population and inefficiency of the therapy without any genetic predictors causing this process of natural selection. In keeping with this notion, cells surviving TRAIL-treatment within a population have been identified as the primary source for secreted cytokines such as interleukin 8 (IL-8) [223]. Moreover, overexpression of TRAIL-R1/R2, and engagement of an agonistic antibody with TRAIL-R2 can induce the release of inflammatory cytokines in an NF-κB-dependent manner [224]. The cancer microenvironment is permanently governed by these inflammatory factors described as a hallmark of cancer to protect the tumour and drive its progression [148]. Monotherapy with TRAIL and acquired resistance or resulting resistance from fractional killing may, therefore, promote the modulation of the tumour-promoting and -protecting microenvironment. Vice versa, the microenvironment seems to regulate TRAIL sensitivity of tumour cells via DcRs expressed on stromal cells [146].

5. Strategies to Regain TRAIL Sensitivity—The Bench-to-Bedside TRAIL

So far, most clinical studies evaluating TRAs have been discontinued due to insufficient anti-tumour effects. A fundamental reason is the intrinsic or acquired TRAIL resistance of cancer cells. Fortuitously, the various levels of regulation within the TRAIL-induced apoptotic pathway which can provoke resistance to apoptotic signals, offer equal opportunities to sensitise cancer cells to TRAIL-induced apoptosis [13,87]. Whilst mechanisms that mediate resistance to TRAIL in non-malignant cells are not entirely uncovered, it is questionable and unpredictable if
TRAIL-sensitising strategies are limited to cancer cells or may also affect healthy cells. In cells that express both death-inducing TRAIL-Rs, heterocomplexation was observed [225], although it is still obscure whether this phenomenon has a unique signalling function. Nevertheless, it would be advantageous to target both, TRAIL-R1 and TRAIL-R2, in tumours considering the tissue-dependent preference of one receptor. In an effort to overcome TRAIL resistance, the ligand has been combined with other anti-cancer drugs or with nature-derived products to enhance cell sensitivity, respectively, and more potent TRAs have been developed. Several TRAs are presented in Figure 2. A variety of sensitising strategies can be found in the literature and have been reviewed in depth [13,14,87]. Unfortunately, many of these approaches had not been verified in animal models, and therefore possible toxicity has been ignored. Therefore, in the following section, only sensitising approaches with a high chance for quick and efficient clinical translation will be discussed.

5.1. Highly Potent TRAs

TRAIL engages three receptors, each at the interface between two of its cysteine-rich domains. The trimer is stabilised via a zinc atom bound by cysteines that is crucial for its biological activity [226,227]. TRAs lacking the critical central atom were poorly soluble and tended to aggregate, presumably conveying liver toxicity [228,229]. Aggregated TRAIL can evoke increased immunogenicity when epitopes are exposed that are usually hidden. An untagged variant including stoichiometric zinc did not provoke significant hepatotoxicity [228].

Tags at the N-terminus of the extracellular domain of TRAIL, such as FLAG™ (peptide sequence DYKDDDDK) and poly-histidine (His, His6-Tag) aid purification of the ligand. Leucine zipper (LZ) and isoleucine zipper (iz) stabilise TRAIL trimers thereby increasing their agonistic potential [3,120]. Since liver toxicity of His-TRAIL and antibody-crosslinked FLAG-TRAIL has been reported, safety concerns were noted for these variants and research on non-tagged variants has been intensified [120,228,230]. Presumably, these safety concerns are causative for untagged dulanermin entering clinical trials. A hepatotoxicity of LZ- and iz-TRAIL, however, could be excluded and a safe in vivo application has been performed [3,120,231].

Due to their bivalent binding mode, agonistic TRAIL-R antibodies are not able to induce higher crosslinking of TRAIL-Rs leading to insufficient DISC activation and weak apoptotic signals compared to the tagged variants of TRAIL [114]. The crosslinking capacity is limited by the absence of adequate Fcγ receptors in the surrounding of cancer cells [114,232]. The aim is therefore to obtain an antibody multimerisation resulting in TRAIL-R-clustering on cancer cells and amplified apoptosis induction. For this reason, research into novel, stable TRAs suited for this purpose is pressing ahead [13,87,233]. A further effort to amplify the DISC signal can be the combined treatment with rhTRAIL and TRAIL-R-targeting antibodies binding to distinct receptor epitopes, thereby enhancing DISC formation and apoptosis induction [234].

Prolonged half-life and an increased tendency for oligomerisation was achieved by the fusion of TRAIL to the Fc portion of human IgG1 (Fc-TRAIL). Although the capacity for apoptosis induction was higher in vivo and in vitro, no liver toxicity was observed [122].

A recent development is a hexavalent TRA, designed by the fusion of two trimers of the extracellular part of TRAIL to the Fc portion of human IgG1 (APG350) thereby creating six receptor binding sites per drug molecule [124]. Recently, the superiority of APG350 over soluble TRAIL has been studied in pancreatic cancer in vitro and xenograft models [235]. Whilst Bcl-xL overexpression rendered cells resistant, sensitivity could be re-established when cells were additionally treated with the BH3 mimetic navitoclax (see Section 5.4 BH3 and SMAC mimetics plus TRAIL) [235,236]. Although APG350 showed encouraging preclinical results, the urgent need for predictive biomarkers and TRAIL sensitising strategies is highlighted through its evaluation in Bcl-xL expressing cells. The formation of higher-order complexes induced by APG350 is not sufficient to overcome blocked mitochondrial apoptosis.
The tumour microenvironment is known to influence the therapy response negatively [113]. DcRs on stromal cells influence TRAIL resistance [146], and, in turn, as recently reported, a TRAIL-induced cancer secretome triggers a tumour-promoting microenvironment [148]. These facts illustrate the relevance of the tumour microenvironment when considering TRAIL-based therapies. The bispecific, tetravalent fibroblast-activation protein (FAP)-TRAIL-R2 antibody, RG7386, targets cancer-associated fibroblasts in the tumour stroma and TRAIL-R2 on tumour cells simultaneously thereby inducing higher-order clustering and apoptosis induction in vitro and animal models. The approach showed promise as monotherapy as well as in combination with chemotherapeutics [125].

5.2. Chemo- and Radiotherapy Plus TRAIL

Additive effects of standard chemotherapeutic agents such as gemcitabine, irinotecan, and cisplatin together with TRAIL have been extensively tested in preclinical models [237]. Furthermore, radiotherapy was proven to synergistically induce apoptosis in combination with TRAIL [238]. Modified receptor expression, enhanced DISC formation, and influence on pro- and anti-apoptotic protein expression are amongst the presumed mechanisms leading to the chemo- and radiotherapy-induced sensitisation. These findings laid the foundation for the combination with TRAs also in clinical studies, so far with marginal effects. Hitherto CPT is an exception, since the ORR of the combined treatment arm was increased in comparison to treatment with chemotherapy alone [131].

The 26S proteasome inhibitor bortezomib is used in MM care and is applied also in other malignancies including breast cancer, colon cancer, and prostate cancer [239]. The exact mode of action of bortezomib is revealed bit by bit. At the TRAIL-R level, a shift of the apoptotic signals from TRAIL-R1 to TRAIL-R2 by internalisation and degradation of TRAIL-R1 could be observed [240]. It also seems that a crosstalk of apoptosis and autophagy plays a central role [241–243]. TRAIL’s part in the regulation of the autophagosome formation is dependent on the expression of the ATG proteins ATG5, ATG7, and beclin-1. This TRAIL-induced ATG expression was weakened by JNK. In combination with bortezomib the activation of extracellular signal-regulated kinase (ERK) has been shown to induce autophagy [244]. Conversely, the inhibitory role of sustained activation of ERK has also been demonstrated. Bortezomib may block the autophagic flux by induction of ERK phosphorylation [243]. The evidence-based sensitisation capacity for TRAIL-induced apoptosis directed the substance to clinical trials combined with the TRAIL-R2 specific TRA mapatumumab. Again, an additive therapeutic advantage was not detectable mainly due to the failure of the antibody for to sufficiently crosslink TRAIL-Rs (see Section 5.1 Highly potent TRAs) [87].

5.3. Inhibition of Anti-Apoptotic c-FLIP in Combination with TRAIL

c-FLIP is an essential anti-apoptotic regulator and can suppress TRAIL-mediated apoptosis [245]. Coming back to the clinical studies investigating CPT (see Section 4.1 TRAs in Clinical Studies—Can Failure still lead to Success?), the therapy was efficient in 20–30% of the patients. The remaining 70% were nevertheless resistant to CPT. Analysing the reasons, elevated expression of c-FLIP in RRMM patients was striking [246] which may mediate resistance to CPT by inhibiting the DISC. Prior experiments already demonstrated the sensitisation of human melanoma cells to TRAIL by suppression of c-FLIP [245]. In a recent study, resistance to CPT was counteracted in MM in vitro and in vivo by downregulation of c-FLIP by rocaglamide (Figure 1) [246]. Rocaglamides are phytochemicals with cancer inhibiting abilities [247]. The natural product in combination with TRAIL also generated impactful in vitro action in additional cancer entities including renal carcinoma [248] and hepatocellular carcinoma (HCC) [249].

5.4. BH3 and SMAC Mimetics Plus TRAIL

The mitochondrial pathway of apoptosis is an important starting point for TRAIL sensitisation since high IAP expression correlates with drug resistance and tumour progression [250]. Small-molecule inhibitors have been designed which mimic the XIAP-binding site of SMAC thereby
antagonising multiple members of the IAP family in the mitochondrial apoptosis cascade (Figure 1). Hitherto, the preclinical evidence [251,252] and first clinical studies [253,254] of these SMAC mimetics indicate a particular aptitude for anticancer therapy as a single agent or in combination with chemotherapeutic drugs. Their real capability as TRAIL sensitiser has already been analysed in a broad range of cancers [192]. Thus, the SMAC mimetic birinapant made it into a clinical trial in ovarian cancer in combination with the TRAIL-R2 agonist conatumumab. In the phase 1b study the tolerability of the combinatorial approach was proven [255]. Future studies will reflect the actual suitability of the substances as a treatment regimen.

Bcl-2 family members govern cell fate in the mitochondrial apoptosis pathway. Overexpression of the anti-apoptotic relatives Bcl-2, Bcl-xL, and Mcl-1 mediates resistance to apoptosis signals and is a frequent feature among human cancers. To re-sensitise cells to apoptotic signals, BH3 mimetics have been established to conquer the anti-apoptotic Bcl-2 family members (Figure 1) [256]. Candidates that reached clinical phases are ABT-199 (venetoclax) directed against Bcl-2, and ABT-263 (navitoclax) antagonising Bcl-2 and Bcl-xL [257–261]. The treatment-related effects of BH3 mimetics were striking. Hence, an orally bioavailable form of venetoclax was approved in 2016 by the United States Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) [262]. An effective synergism of navitoclax and venetoclax together with TRAIL was observed in vitro [263,264]. The clinical TRA candidate ABBV-621 induced apoptosis alone and enhanced in combination with navitoclax and venetoclax in haematological tumours [133]. According to these studies, SMAC mimetics, and BH3 mimetics might be a suitable class of sensitisers emerging from experimentation to overcome resistance to TRAIL-induced apoptosis in patient trials.

6. Conclusions and Future Perspectives

During the last decade, research into novel anti-cancer drugs has especially revolved around the discovery of specifically-targeted, side effect-reduced approaches. In this context, the discovery of the tumour selectiveness of apoptosis induction by TRAIL in the late 90s was thought to be a breakthrough and research into TRAIL-induced signalling pathways has been intensified. Following favourable preclinical results of tumour cell-selective apoptosis induction, recombinant forms of TRAIL and TRAIL-R-targeting antibodies have been evaluated in clinical trials, though with sobering outcome in most cases. The drawbacks have been outlined above as well as strategies to overcome TRAIL resistance. Novel, highly potent TRAs have been designed. By the use of high-throughput screenings (HTS), the identification and development of these TRAs can become more efficient. Although the TRAs with improved agonistic potential may finally boast the desired antitumor effect in clinical settings, overcoming TRAIL resistance remains a struggle ahead. There is a stable demand for highly-potent and adverse effect-reduced TRAIL sensitisers without losing sight of possible, fulminant adverse effects. For more appropriate pre-clinical testing, humanised and patient-derived preclinical mouse models are warranted. Moreover, predictive biomarkers are urgently needed to identify responding patients or to follow therapy response more precisely. To date, everything suggests that CPT will perform superior to conventional chemotherapy in haematological malignancies. In case that this approach can be validated for other tumour entities, and efficient sensitisers such as SMAC and BH3 mimetics can be clinically validated in combination, targeting this receptor/ligand system might just turn out to be a “TRAILblazer” in cancer therapy.

Author Contributions: The study was designed by J.L., D.H.-B., and S.v.K. Literature was collected by A.-L.K. and A.H., figures were devised by A.-L.K. and J.L., A.-L.K., S.v.K., A.T., and U.K. wrote the manuscript. All authors read and approved the manuscript.

Funding: This work was funded by a research fellowship from the Deutsche Forschungsgemeinschaft (DFG) to J.L.; S.v.K. is funded through the Max-Eder-Programme of the German Cancer Aid.

Conflicts of Interest: The authors declare no conflict of interest.
### Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| AMPK         | AMP-activated protein kinase |
| Apaf-1       | protease activating factor-1 |
| Apo2L        | Apo-2 ligand |
| ATG          | autophagy-related genes |
| Bak          | Bcl-2 antagonist or killer |
| Bax          | Bcl-2-associated X protein |
| Bcl-2        | B-cell CLL/lymphoma 2 |
| Bcl-xL       | B-cell lymphoma-extra-large |
| BH           | Bcl-2 homology |
| Bid          | BH3-only protein |
| BIR          | baculovirus IAP repeat |
| CLL          | chronic lymphocytic leukemia |
| CTC          | circulating tumour cells |
| c-FLIPL      | cellular (FADD-like IL-1β-converting enzyme)-inhibitory protein |
| c-FLIPs      | c-FLIP short |
| cIAP         | cellular inhibitor of apoptosis protein |
| CPT          | circularly permuted TRAIL |
| DD           | death domain |
| DED          | death effector domains |
| DISC         | death-inducing signalling complex |
| DLT          | dose-limiting toxicity |
| DR           | death receptor |
| ERK          | extracellular signal-regulated kinases |
| FADD         | Fas-associated death domain |
| FAP          | fibroblast-activation protein |
| Fc           | fragment crystallizable region |
| FDA          | United States Food and Drug Administration |
| FOLFIRI      | folinic acid, fluorouracil, irinotecan |
| GALNT14      | polypeptide N-acetylgalactosaminyltransferase 14 |
| GPI          | glycosylphosphatidylinositol |
| HCC          | hepatocellular carcinoma |
| HSA          | human serum albumin |
| HTS          | high-throughput screenings |
| IgG          | Immunoglobulin G |
| IKK          | inhibitor of κB kinase |
| IL           | interleukin |
| iz           | isoleucin |
| IκB          | inhibitor of κB |
| JNK          | c-Jun N-terminal kinases |
| KRAS         | Kirsten rat sarcoma |
| LUBAC        | linear ubiquitin chain assembly complex |
| MAPK         | mitogen-activated protein kinase |
| Mcl-1        | myeloid leukaemia cell differentiation protein |
| miRNA        | microRNA |
| MOM          | mitochondrial outer membrane |
| MOMP         | mitochondrial outer membrane permeabilization |
| LZ           | leucine zipper |
MPD  membrane-proximal domain
MTD  maximum tolerated dose
mTOR mechanistic target of rapamycin
NEMO  NF-xB essential modifier
NF-xB nuclear factor kappa-light-chain-enhancer of activated B cells
NIAP neuronal apoptosis inhibitory protein
NSCLC  non-small-cell lung cancer
OPG osteoprotegerin
ORR  objective response rate
OS  overall survival
PFS progression-free survival
pI  isoelectric point
PI3K  tyrosine kinase Src and phosphoinositide 3-kinase
PUMA  p53 upregulated modulator of apoptosis
Rac1  Ras-related C3 botulinum toxin substrate 1
rhTRAIL recombinant human TRAIL
RIPK receptor-interacting protein kinase
RRMM relapsed refractory multiple myeloma
scTRAIL  single-chain TRAIL
SMAC/DIABLO  second mitochondrial activator of caspases/direct inhibitor of apoptosis-binding protein with low pI
SR  superfamily
tBID truncated BH3-only protein
TD  thalidomide/dexamethasone
TNF  tumor necrosis factor
TNF-SF  TNF-superfamily
TRAF2  TNF receptor-associated factor-2
TRA E  treatment-related adverse events
TRAIL  TNF-related apoptosis-inducing ligand
TRAIL-R  TRAIL receptor
TRA  TRAIL receptor agonist
Ts-IAP  testis-specific IAP
USP8  ubiquitin-specific peptidase 8
VHH  high-affinity heavy chain domain
XIAP  X-linked inhibitor of apoptosis protein

References

1. Wiley, S.R.; Schooley, K.; Smolak, P.J.; Din, W.S.; Huang, C.P.; Nicholl, J.K.; Sutherland, G.R.; Smith, T.D.; Rauch, C.; Smith, C.A.; et al. Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity* 1995, 3, 673–682. [CrossRef]

2. Pitti, R.M.; Marsters, S.A.; Ruppert, S.; Donahue, C.J.; Moore, A.; Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. *J. Biol. Chem.* 1996, 271, 12687–12690. [CrossRef] [PubMed]

3. Walczak, H.; Miller, R.E.; Ariail, K.; Gliniak, B.; Griffith, T.S.; Kubin, M.; Chin, W.; Jones, J.; Woodward, A.; Le, T.; et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. *J. Biol. Chem.* 1999, 271, 12687–12690. [CrossRef] [PubMed]

4. Ashkenazi, A.; Pai, R.C.; Fong, S.; Leung, S.; Lawrence, D.A.; Marsters, S.A.; Blackie, C.; Chang, L.; McMurtrey, A.E.; Hebert, A.; et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. *J. Clin. Investig.* 1999, 104, 155–162. [CrossRef] [PubMed]

5. Pan, G.; Ni, J.; Wei, Y.F.; Yu, G.; Gentz, R.; Dixit, V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science (N. Y.)* 1997, 277, 815–818. [CrossRef]
6. Walczak, H.; Degli-Esposti, M.A.; Johnson, R.S.; Smolak, P.J.; Waugh, J.Y.; Boiani, N.; Timour, M.S.; Gerhart, M.J.; Schooley, K.A.; Smith, C.A.; et al. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. *EMBO J.* 1997, 16, 5386–5397. [CrossRef] [PubMed]

7. Hymowitz, S.G.; Christinger, H.W.; Fuh, G.; Ullsch, M.; O’Connell, M.; Kelley, R.F.; Ashkenazi, A.; de Vos, A.M. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5. *Mol. Cell* 1999, 4, 563–571. [CrossRef]

8. Mongkolsapaya, J.; Grimes, J.M.; Chen, N.; Xu, X.N.; Stuart, D.I.; Screaton, G.R. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. *Nat. Struct. Biol.* 1999, 6, 103–1053.

9. Degli-Esposti, M.A.; Dougall, W.C.; Smolak, P.J.; Waugh, J.Y.; Smith, C.A.; Goodwin, R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. *Immunity* 1997, 7, 813–820. [CrossRef]

10. Emery, J.G.; McDonnell, P.; Burke, M.B.; Deen, K.C.; Lyn, S.; Silverman, C.; Dul, E.; Appelbaum, E.R.; Eichman, C.; DiPrinzio, R.; et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. *J. Biol. Chem.* 1998, 273, 14363–14367. [CrossRef]

11. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. *Nat. Rev. Cancer* 2002, 2, 420–430. [CrossRef]

12. LeBlanc, H.N.; Ashkenazi, A. Apo2L/TRAIL and its death and decoy receptors. *Cell Death Differ.* 2003, 10, 66–75. [CrossRef]

13. De Miguel, D.; Lemke, J.; Anel, A.; Walczak, H.; Martinez-Lostao, L. Onto better TRAILs for cancer treatment. *Cell Death Differ.* 2016, 23, 733–747. [CrossRef] [PubMed]

14. Von Karstedt, S.; Montinaro, A.; Walczak, H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. *Nat. Rev. Cancer* 2017, 17, 352–366. [CrossRef]

15. Pan, G.; O’Rourke, K.; Chinnaiyan, A.M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V.M. The receptor for the cytotoxic ligand TRAIL. *Science (N. Y.)* 1997, 276, 111–113. [CrossRef]

16. Sheridan, J.P.; Marsters, S.A.; Pitti, R.M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C.L.; Baker, K.; Wood, W.I.; et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science (N. Y.)* 1997, 277, 818–821. [CrossRef]

17. Marsters, S.A.; Sheridan, J.P.; Pitti, R.M.; Huang, A.; Skubatch, M.; Baldwin, D.; Yuan, J.; Gurney, A.; Goddard, A.D.; Godowski, P.; et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Curr. Biol.* 1997, 7, 1003–1006. [CrossRef]

18. Simonet, W.S.; Lacey, D.L.; Dunstan, C.R.; Kelley, M.; Chang, M.S.; Luthy, R.; Nguyen, H.Q.; Wooden, S.; Bennett, L.; Boone, T.; et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. *Cell* 1997, 89, 309–319. [CrossRef]

19. Takahashi, N.; Udagawa, N.; Suda, T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. *Biochem. Biophys. Res. Commun.* 1999, 256, 449–455. [CrossRef]

20. Truneh, A.; Sharma, S.; Silverman, C.; Khandekar, S.; Reddy, M.P.; Deen, K.C.; McLaughlin, M.M.; Srinivasula, S.M.; Livy, G.P.; Marshall, L.A.; et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. *J. Biol. Chem.* 2000, 275, 23319–23325. [CrossRef] [PubMed]

21. Lemke, J.; Noack, A.; Adam, D.; Tchikov, V.; Bertsch, U.; Roder, C.; Schutze, S.; Wajant, H.; Kalthoff, H.; Trauздold, A. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. *J. Mol. Med.* 2010, 88, 729–740. [CrossRef] [PubMed]

22. Stadel, D.; Mohr, A.; Ref, C.; MacFarlane, M.; Zhou, S.; Humphreys, R.; Bachem, M.; Cohen, G.; Moller, P.; Zwaсka, R.M.; et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 2010, 16, 5734–5749. [CrossRef] [PubMed]

23. MacFarlane, M.; Inoue, S.; Kohlihaas, S.L.; Majid, A.; Harper, N.; Kennedy, D.B.; Dyer, M.J.; Cohen, G.M. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. *Cell Death Differ.* 2005, 12, 773–782. [CrossRef] [PubMed]
24. MacFarlane, M.; Kohlhaas, S.L.; Sutcliffe, M.J.; Dyer, M.J.; Cohen, G.M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. *Cancer Res.* 2005, 65, 11265–11270. [CrossRef] [PubMed]

25. Wu, G.S.; Burns, T.F.; Zhan, Y.; Alnemri, E.S.; El-Deiry, W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. *Cancer Res.* 1999, 59, 2770–2775.

26. Bossen, C.; Ingold, K.; Tardivel, A.; Bodmer, J.L.; Gaide, O.; Hertig, S.; Ambrose, C.; Tschopp, J.; Schneider, P. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. *J. Biol. Chem.* 2006, 281, 13964–13971. [CrossRef] [PubMed]

27. Chaudhary, P.M.; Eby, M.; Jasmin, A.; Bookwalter, A.; Murray, J.; Hood, L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. *Immunity* 1997, 7, 821–830. [CrossRef]

28. Wang, T.T.; Jeng, J. Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells. *Breast Cancer Res. Treat.* 2000, 61, 87–96. [CrossRef] [PubMed]

29. Fridman, J.S.; Lowe, S.W. Control of apoptosis by p53. *Oncogene* 2003, 22, 9030–9040. [CrossRef]

30. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* 1972, 26, 239–257. [CrossRef] [PubMed]

31. Hengartner, M.O. The biochemistry of apoptosis. *Nature* 2000, 407, 770–776. [CrossRef]

32. Brenner, D.; Mak, T.W. Mitochondrial cell death effectors. *Curr. Opin. Cell Biol.* 2009, 21, 871–877. [CrossRef] [PubMed]

33. Kalkavan, H.; Green, D.R. MOMP, cell suicide as a BCL-2 family business. *Cell Death Differ.* 2018, 25, 46–55. [CrossRef] [PubMed]

34. Wallace-Brodeur, R.R.; Lowe, S.W. TRAIL and apoptosis induction by TNF-family death receptors. *Oncogene* 2003, 22, 8628–8633. [CrossRef] [PubMed]

35. Favaloro, B.; Allocati, N.; Graziano, V.; Di Ilio, C.; De Laurenzi, V. Role of apoptosis in disease. *Aging* 2012, 4, 330–349. [CrossRef]

36. Burke, P.J. Mitochondria, Bioenergetics and Apoptosis in Cancer. *Trends Cancer* 2017, 3, 857–870. [CrossRef] [PubMed]

37. Varfolomeev, E.; Mæcker, H.; Sharp, D.; Lawrence, D.; Renz, M.; Vucic, D.; Ashkenazi, A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. *J. Biol. Chem.* 2005, 280, 40599–40608. [CrossRef] [PubMed]

38. Hacker, H.; Karin, M. Regulation and function of IKK and IKK-related kinases. *Sci. STKE Signal Transduct. Knowl. Environ.* 2006, re13. [CrossRef] [PubMed]

39. Karl, I.; Jossberger-Werner, M.; Schmidt, N.; Horn, S.; Goebeler, M.; Leverkus, M.; Wajant, H.; Giner, T. TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis. *Cell Death Dis.* 2014, 5, e1444. [CrossRef] [PubMed]

40. Von Karstedt, S.; Conti, A.; Nobis, M.; Montinaro, A.; Hartwig, T.; Reichert, M.; Kupka, S.; Shimizu, Y.; Taraborrelli, L.; Spit, M.; et al. The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. *EMBO J.* 2017, 36, 1147–1166. [CrossRef] [PubMed]

41. Azijli, K.; Yuvaraj, S.; Peppelenbosch, M.P.; Wurdinger, T.; Dekker, H.; Joore, J.; van Dijk, E.; Quax, W.J.; Peters, G.J.; de Jong, S.; et al. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. *J. Cell Sci.* 2012, 125 Pt 19, 4651–4661. [CrossRef]

42. Von Karstedt, S.; Conti, A.; Nobis, M.; Montinaro, A.; Hartwig, T.; Lemke, J.; Legler, K.; Annenwerter, F.; Campbell, A.D.; Taraborrelli, L.; et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. *Cancer Cell* 2015, 27, 561–573. [CrossRef] [PubMed]

43. Haselmann, V.; Kurz, A.; Bertsch, U.; Hubner, S.; Olempska-Muller, M.; Fritsche, J.; Hasler, R.; Pickl, A.; Fritsche, H.; Annenwerter, F.; et al. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. *Gastroenterology* 2014, 146, 278–290. [CrossRef] [PubMed]
45. Sprick, M.R.; Weigand, M.A.; Rieser, E.; Rauch, C.T.; Juo, P.; Blenis, J.; Krammer, P.H.; Walczak, H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. *Immunity* 2000, 12, 599–609. [CrossRef] [PubMed]

46. Kischkel, F.C.; Lawrence, D.A.; Tinel, A.; LeBlanc, H.; Virmani, A.; Schow, P.; Gazdar, A.; Blenis, J.; Arnott, D.; Ashkenazi, A. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. *J. Biol. Chem.* 2001, 276, 46639–46646. [CrossRef] [PubMed]

47. Sprick, M.R.; Rieser, E.; Stahl, H.; Grosse-Wilde, A.; Weigand, M.A.; Walczak, H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. *EMBO J.* 2002, 21, 4520–4530. [CrossRef] [PubMed]

48. Bodmer, J.L.; Holler, N.; Reynard, S.; Vinciguerra, P.; Schneider, P.; Juo, P.; Blenis, J.; Tschopp, J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. *Nat. Cell Biol.* 2000, 2, 241–243. [CrossRef] [PubMed]

49. Dickens, L.S.; Boyd, R.S.; Jukes-Jones, R.; Hughes, M.A.; Robinson, G.L.; Fairall, L.; Schwabe, J.W.; Cain, K.; Macfarlane, M. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. *Mol. Cell* 2012, 47, 54–63. [CrossRef] [PubMed]

50. Schleich, K.; Buchbinder, J.H.; Pietkiewicz, S.; Kahne, T.; Wärnken, U.; Ozturk, S.; Schnolzer, M.; Naumann, M.; Krammer, P.H.; Lavrik, I.N. Molecular architecture of the DED chains at the DISC: Regulation of caspase-8 activation by short DED proteins c-FLIP and procaspase-8. *Cell Death Differ.* 2016, 23, 681–694. [CrossRef] [PubMed]

51. Hinshaw-Makepeace, J.; Huston, G.; Fortner, K.A.; Russell, J.Q.; Holoch, D.; Swain, S.; Budd, R.C. C-FLIP(S) reduces activation of caspase and NF-kappaB pathways and decreases T cell survival. *Eur. J. Immunol.* 2008, 38, 54–63. [CrossRef] [PubMed]

52. Dillon, C.P.; Oberst, A.; Weinlich, R.; Janke, L.J.; Kang, T.B.; Ben-Moshe, T.; Mak, T.W.; Wallach, D.; Green, D.R. Survival function of the FADD-CASPASE-8-cFLIP complex. *Cell Rep.* 2012, 1, 401–407. [CrossRef] [PubMed]

53. Arhoma, A.; Chantry, A.D.; Haywood-Small, S.L.; Cross, N.A. SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture. *Exp. Cell Res.* 2017, 360, 226–235. [CrossRef] [PubMed]

54. Hughes, M.A.; Powley, I.R.; Jukes-Jones, R.; Horn, S.; Feoktistova, M.; Fairall, L.; Schwabe, J.W.R.; Leverkus, M.; Cain, K.; MacFarlane, M. Co-operative and Hierarchical Binding of c-FLIP and Caspase-8: A Unified Model Defines How c-FLIP Isoforms Differentially Control Cell Fate. *Mol. Cell* 2016, 61, 834–849. [CrossRef] [PubMed]

55. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J.L.; Schroter, M.; Burns, K.; Mattmann, C.; et al. Inhibition of death receptor signals by cellular FLIP. *Nature* 1997, 388, 190–195. [CrossRef] [PubMed]

56. Ozturk, S.; Schleich, K.; Lavrik, I.N. Cellular FLICE-like inhibitory proteins (c-FLIPs): Fine-tuners of life and death decisions. *Exp. Cell Res.* 2012, 318, 1324–1331. [CrossRef] [PubMed]

57. Fricker, N.; Beaudouin, J.; Richter, P.; Eils, R.; Krammer, P.H.; Lavrik, I.N. Model-based dissection of CD95 signaling dynamics reveals both a pro- and antia apoptotic role of c-FLIPL. *J. Cell Biol.* 2010, 190, 377–389. [CrossRef] [PubMed]
62. Micheau, O.; Thome, M.; Schneider, P.; Holler, N.; Tschopp, J.; Nicholson, D.W.; Briand, C.; Grutter, M.G. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 2002, 277, 45162–45171. [CrossRef] [PubMed]

63. Yu, J.W.; Jeffrey, P.D.; Shi, Y. Mechanism of procaspase-8 activation by c-FLIPL. Proc. Natl. Acad. Sci. USA 2009, 106, 8169–8174. [CrossRef] [PubMed]

64. Boatright, K.M.; Deis, C.; Denault, J.B.; Sutherland, D.P.; Salvesen, G.S. Activation of caspases-8 and -10 by FLIP (L). Biochem. J. 2004, 382 Pt 2, 651–657. [CrossRef]

65. Oberst, A.; Dillon, C.P.; Weinlich, R.; McCormick, P.; Pop, C.; Hakem, R.; Salvesen, G.S.; Green, D.R. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011, 471, 363–367. [CrossRef] [PubMed]

66. Deng, Y.; Lin, Y.; Wu, X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 2002, 16, 33–45. [CrossRef] [PubMed]

67. LeBlanc, H.; Lawrence, D.; Varfolomeev, E.; Topal, K.; Morlan, J.; Schow, P.; Fong, S.; Schwall, R.; Sinicropi, D.; Ashkenazi, A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bel-2 homolog Bax. Nat. Med. 2002, 8, 274–281. [CrossRef] [PubMed]

68. Ozoren, N.; El-Deiry, W.S. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (N. Y.) 2002, 4, 551–557. [CrossRef] [PubMed]

69. Jost, P.J.; Grabow, S.; Gray, D.; McKenzie, M.D.; Nachbur, U.; Huang, D.C.S.; Bouillet, P.; Thomas, H.E.; Borner, C.; Silke, J.; et al. XIAP acts as a switch between type I and type II FAS-induced apoptosis signalling. Nature 2009, 460, 1035–1039. [CrossRef] [PubMed]

70. Deveraux, Q.L.; Roy, N.; Stennicke, H.R.; Van Arsdale, T.; Zhou, Q.; Srinivasula, S.M.; Alnemri, E.S.; Salvesen, G.S.; Reed, J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17, 2215–2223. [CrossRef]

71. Holcik, M.; Korneluk, R.G. XIAP, the guardian angel. Nat. Rev. Mol. Cell Biol. 2001, 2, 550–556. [CrossRef] [PubMed]

72. Bratton, S.B.; Walker, G.; Srinivasula, S.M.; Sun, X.M.; Butterworth, M.; Alnemri, E.S.; Cohen, G.M. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J. 2001, 20, 998–1009. [CrossRef] [PubMed]

73. Luo, X.; Budihardjo, I.; Zou, H.; Slaughter, C.; Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94, 481–490. [CrossRef]

74. Antonsson, B.; Montessuit, S.; Sanchez, B.; Martinou, J.C. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J. Biol. Chem. 2001, 276, 11615–11623. [CrossRef] [PubMed]

75. Dewson, G.; Kratina, T.; Czabotar, P.; Day, C.L.; Adams, J.M.; Kluck, R.M. Bak activation for apoptosis involves oligomerization of dimers via their alpha helices. Mol. Cell 2009, 36, 696–703. [CrossRef]

76. Huang, K.; Zhang, J.; O'Neill, K.L.; Gurumurthy, C.B.; Quadros, R.M.; Tu, Y.; Luo, X. Cleavage by Caspase 8 and Mitochondrial Membrane Association Activate the BH3-only Protein Bid during TRAIL-induced Apoptosis. J. Biol. Chem. 2016, 291, 11843–11851. [CrossRef]

77. Riedl, S.J.; Salvesen, G.S. The apoptosisosome: Signalling platform of cell death. Nat. Rev. Mol. Cell Biol. 2007, 8, 405–413. [CrossRef] [PubMed]

78. Falschlehner, C.; Emmerich, C.H.; Gerlach, B.; Walczak, H. TRAIL signalling: Decisions between life and death. Int. J. Biochem. Cell Biol. 2007, 39, 1462–1475. [CrossRef] [PubMed]

79. Sarosiek, K.A.; Fraser, C.; Muthalagu, N.; Bhola, P.D.; Chang, W.; McBrayer, S.K.; Cantlon, A.; Fisch, S.; Golomb-Mello, G.; Ryan, J.A.; et al. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell 2017, 31, 142–156. [CrossRef]

80. Zhang, X.D.; Nguyen, T.; Sanders, J.E.; Hersey, P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEMS Lett. 2000, 482, 193–199.

81. Singh, H.D.; Otano, I.; Rombouts, K.; Singh, K.P.; Peppa, D.; Gill, U.S.; Böttcher, K.; Kennedy, P.T.F.; Oben, J.; Pinzani, M.; et al. TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Sci. Rep. 2017, 7, 5514. [CrossRef] [PubMed]
82. Merino, D.; Lalaoui, N.; Morizot, A.; Schneider, P.; Solary, E.; Micheau, O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. *Mol. Cell. Biol.* 2006, 26, 7046–7055. [CrossRef]
83. Micheau, O.; Lens, S.; Gaide, O.; Alevizopoulos, K.; Tschopp, J. NF-kappaB signals induce the expression of c-FLIP. *Mol. Cell. Biol.* 2001, 21, 5299–5305. [CrossRef] [PubMed]
84. Van Dijk, M.; Halpin-McCormick, A.; Sessler, T.; Samali, A.; Szegedi, E. Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. *Cell Death Dis.* 2013, 4, e702. [CrossRef]
85. Llambi, F.; Moldoveanu, T.; Tait, S.W.; Bouchier-Hayes, L.; Temirov, J.; McCormick, L.L.; Dillon, C.P.; Green, D.R. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. *Mol. Cell* 2011, 44, 517–531. [PubMed]
86. Willis, S.N.; Chen, L.; Dewson, G.; Wei, A.; Naik, E.; Fletcher, J.I.; Adams, J.M.; Huang, D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. *Genes Dev.* 2005, 19, 1294–1305. [CrossRef]
87. Lemke, J.; von Karstedt, S.; Zinngrebe, J.; Walczak, H. Getting TRAIL back on track for cancer therapy. *Cell Death Differ.* 2014, 21, 1350–1364. [CrossRef] [PubMed]
88. Kretz, A.L.; von Karstedt, S.; Hillenbrand, A.; Henne-Bruns, D.; Knippschild, U.; Trauzold, A.; Lemke, J. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. *Cancers* 2018, 10, 77. [CrossRef] [PubMed]
89. Balkwill, F. Tumour necrosis factor and cancer. *Nat. Rev. Cancer* 2009, 9, 361–371. [CrossRef] [PubMed]
90. Roberts, N.J.; Zhou, S.; Diaz, L.A., Jr.; Holdhoff, M. Systemic use of tumor necrosis factor alpha as an anticancer agent. *Oncotarget* 2011, 2, 739–751. [CrossRef]
91. Soria, J.C.; Smit, E.; Khayat, D.; Besse, B.; Yang, X.; Hsu, C.P.; Reese, D.; Wiezorek, J.; Blackhall, F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2010, 28, 1527–1533. [CrossRef]
92. Yee, L.; Fanale, M.; Dimick; K.; Calvert, S.; Robins, C.; Ling, I.; Novotny, W.; Ashkenazi, A.; III. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. *J. Clin. Oncol.* 2007, 25 (Suppl. 18), 8078.
93. Yee, L.; Burrhis, H.A.; Kozloff, M.; Wainberg, Z.; Pao, M.; Skettino, S.; Novotny, W.; Durbin, B.; Weston, J.; Hurwitz, H. Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results. *J. Clin. Oncol.* 2009, 27 (Suppl. 15), 4129.
94. Kasubhai, S.M.; Bendell, J.C.; Kozloff, M.; Kapp, A.V.; Ashkenazi, A.; Royer-Joo, S.; Portera, C.C. Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). *J. Clin. Oncol.* 2012, 30 (Suppl. 15), 3543.
95. Wainberg, Z.A.; Messersmith, W.A.; Peddi, P.F.; Kapp, A.V.; Ashkenazi, A.; Royer-Joo, S.; Portera, C.C.; Kozloff, M.F. A phase 1B study of dulanermin in combination with modified FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. *Clin. Color. Cancer* 2013, 12, 248–254. [CrossRef]
96. Herbst, R.S.; Eckhardt, S.G.; Kurzrock, R.; Ebbinghaus, S.; O’Dwyer, P.; Gordon, M.S.; Novotny, W.; Goldwasser, M.A.; Tohnya, T.M.; Lum, B.L.; et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2010, 28, 2839–2846. [CrossRef] [PubMed]
97. Cheah, C.Y.; Belada, D.; Fanale, M.A.; Janikova, A.; Czucman, M.S.; Flinn, I.W.; Kapp, A.V.; Ashkenazi, A.; Kelley, S.; Bray, G.L.; et al. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: An open-label phase 1b/2 randomised study. *Lancet Haematol.* 2015, 2, e166–e174. [CrossRef]
98. Soria, J.C.; Mark, Z.; Zatljoukal, P.; Szima, B.; Albert, I.; Juhasz, E.; Pujol, J.L.; Kozielski, J.; Baker, N.; Smethurst, D.; et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2011, 29, 4442–4451. [CrossRef]
99. Quintavalle, C.; Condorelli, G. Dulanermin in cancer therapy: Still much to do. *Transl. Lung Cancer Res.* 2012, 1, 158–159. [PubMed]
100. Pan, Y.; Xu, R.; Peach, M.; Huang, C.P.; Branstetter, D.; Novotny, W.; Herbst, R.S.; Eckhardt, S.G.; Holland, P.M. Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br. J. Cancer 2011, 105, 1830–1838. [CrossRef]

101. Faller, B.A.; Pandit, T.N. Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clin. Med. Insights Oncol. 2011, 5, 131–144. [CrossRef] [PubMed]

102. Ruiz-Ceja, K.A.; Chirrino, Y.I. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomed. Pharmacother. Biomed. Pharmacother. 2017, 90, 24–37. [CrossRef] [PubMed]

103. Ouyang, X.; Shi, M.; Jie, F.; Bai, Y.; Shen, P.; Yu, Z.; Wang, X.; Huang, C.; Tao, M.; Wang, Z.; et al. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer. Investig. New Drugs 2018, 36, 315–322. [CrossRef] [PubMed]

104. Kaplan-Lefko, P.J.; Graves, J.D.; Zoog, S.J.; Pan, Y.; Wall, J.; Branstetter, D.G.; Moriguchi, J.; Coxon, A.; Huard, J.N.; Xu, R.; et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol. Ther. 2010, 9, 618–631. [CrossRef]

105. Kang, Z.; Chen, J.J.; Yu, Y.; Li, B.; Sun, S.Y.; Zhang, B.; Cao, L. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011, 17, 3181–3192. [CrossRef] [PubMed]

106. Rosevear, H.M.; Lightfoot, A.J.; Griffith, T.S. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. Curr. Opin. Investig. Drugs 2010, 11, 688–698.

107. Sharma, S.; de Vries, E.G.; Infante, J.R.; Oldenhuis, C.N.; Gietema, J.A.; Yang, L.; Bilic, S.; Parker, K.; Goldbrunner, M.; Scott, J.W.; et al. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investig. New Drugs 2014, 32, 135–144. [CrossRef]

108. Forero-Torres, A.; Shah, J.; Wood, T.; Posey, J.; Carlisle, R.; Copigneaux, C.; Luo, F.; Wojtowicz-Praga, S.; Percent, I.; Saleh, M. Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5). Cancer Biother. Radiopharm. 2010, 25, 13–19. [CrossRef]

109. Forero-Torres, A.; Infante, J.R.; Waterhouse, D.; Wong, L.; Vickers, S.; Arrowsmith, E.; He, A.R.; Hart, L.; Trent, D.; Wade, J.; et al. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. Cancer Biother. Radiopharm. 2013, 28, 13–19. [CrossRef]

110. Merchant, M.S.; Geller, J.I.; Baird, K.; Chou, A.J.; Galli, S.; Charles, A.; Amaoko, M.; Rhee, E.H.; Price, A.; Wexler, L.H.; et al. Phase I trial and pharmacokinetic study of lecutumumab in pediatric patients with solid tumors. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012, 30, 4141–4147. [CrossRef] [PubMed]

111. Fuchs, C.S.; Fakih, M.; Schwartzberg, L.; Cohn, A.L.; Yee, L.; Dreisbach, L.; Kozloff, M.F.; Hei, Y.J.; Galimi, F.; Pan, Y.; et al. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer 2013, 119, 4290–4298. [CrossRef]

112. Gillies, R.J.; Schornack, P.A.; Secomb, T.W.; Raghumand, N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia (N. Y.) 1999, 1, 197–207. [CrossRef]

113. Wu, T.; Dai, Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017, 387, 61–68. [CrossRef] [PubMed]

114. Wilson, N.S.; Yang, B.; Yang, A.; Loezser, S.; Marsters, S.; Lawrence, D.; Li, Y.; Petti, R.; Totpal, K.; Yee, S.; et al. An Fc receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011, 19, 101–113. [CrossRef]

115. Dhein, J.; Daniel, P.T.; Trauth, B.C.; Oehm, A.; Möller, P.; Krammer, P.H. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 1992, 149, 3166–3173. [PubMed]

116. Wagner, K.W.; Punnoose, E.A.; Januario, T.; Lawrence, D.A.; Petti, R.M.; Lancaster, K.; Lee, D.; von Goetz, M.; Yee, S.F.; Totpal, K.; et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13, 1070. [CrossRef]
117. Huet, H.A.; Grownney, J.D.; Johnson, J.A.; Li, J.; Bilic, S.; Ostrom, L.; Zafari, M.; Kowal, C.; Yang, G.; Royo, A.; et al. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. mAbs 2014, 6, 1560–1570. [CrossRef]

118. Van Audenhove, I.; Gettemans, J. Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer. Ebiomedicine 2016, 8, 40–48. [CrossRef]

119. Papadopoulos, K.P.; Isaacs, R.; Bilic, S.; Kentsch, K.; Huet, H.A.; Hofmann, M.; Rasco, D.; Kundamal, N.; Tang, Z.; Cooke, J.; et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody(R) targeting the DR5 receptor. Cancer Chemother. Pharmacol. 2015, 75, 887–895. [CrossRef]

120. Ganten, T.M.; Koschny, R.; Sykora, J.; Schulze-Bergkamen, H.; Buchler, P.; Haas, T.L.; Schader, M.B.; Untergasser, A.; Stemmel, W.; Walczak, H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL, either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2006, 12, 2640–2646. [CrossRef] [PubMed]

121. Fang, F.; Wang, A.P.; Yang, S.F. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol. Sin. 2005, 26, 1373–1381. [CrossRef]

122. Wang, H.; Davis, J.S.; Wu, X. Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity. Mol. Cancer Ther. 2014, 13, 643–650. [CrossRef] [PubMed]

123. Schneider, B.; Munkel, S.; Krippner-Heidenreich, A.; Grunwald, I.; Wels, W.S.; Wajant, H.; Pfizenmaier, K.; Gerschach, J. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis. 2010, 1, e68. [CrossRef] [PubMed]

124. Gieffers, C.; Kluge, M.; Merz, C.; Sykora, J.; Thiemann, M.; Schaaf, R.; Fischer, C.; Branschadel, M.; Abhari, B.A.; Hohenberger, P.; et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fc gamma receptors. Mol. Cancer Ther. 2013, 12, 2735–2747. [CrossRef] [PubMed]

125. Brunker, P.; Wartha, K.; Friess, T.; Grau-Richards, S.; Waldhauer, I.; Koller, C.F.; Weiser, B.; Majety, M.; Runza, V.; Niu, H.; et al. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. Mol. Cancer Ther. 2016, 15, 946–957. [CrossRef] [PubMed]

126. Chen, W.; Qiu, L.; Hou, J.; Zhang, X.; Ke, X.; Wang, Z.; Zhou, F.; Yang, S.; Zhao, Y.; Leng, Y.; et al. Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients. Blood 2012, 120, 1857.

127. Leng, Y.; Qiu, L.; Hou, J.; Zhao, Y.; Zhang, X.; Yang, S.; Xi, H.; Huang, Z.; Pan, L.; Chen, W. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chin. J. Cancer 2016, 35, 86. [CrossRef] [PubMed]

128. Ridings, J.E. The thalidomide disaster, lessons from the past. Methods Mol. Biol. 2013, 947, 575–586.

129. Richardson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609–2617. [CrossRef]

130. Geng, C.; Hou, J.; Zhao, Y.; Ke, X.; Wang, Z.; Qiu, L.; Xi, H.; Wang, F.; Wei, N.; Liu, Y.; et al. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Am. J. Hematol. 2014, 89, 1037–1042. [CrossRef] [PubMed]

131. Leng, Y.; Hou, J.; Jin, J.; Zhang, M.; Ke, X.; Jiang, B.; Pan, L.; Yang, L.; Zhou, F.; Wang, J.; et al. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: A phase 2 study. Cancer Chemother. Pharmacol. 2017, 79, 1141–1149. [CrossRef] [PubMed]

132. Dobos, J.; Kenessey, I.; Timar, J.; Ladanyi, A. Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. Pathol. Oncol. Res. 2011, 17, 729–734. [CrossRef] [PubMed]

133. Tahir, S.K.; Smith, M.L.; Solomon, L.R.; Zhang, H.; Xue, J.C.; Xiao, Y.; Cheng, D.; Buchanan, G.; Morgan-Lappe, S.; Phillips, D.C. Abbv-621 Is a Novel and Potent TRAIL Receptor agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors. Blood 2017, 130 (Suppl. 1), 2812.

134. Micheau, O.; Shirley, S.; Dufour, F. Death receptors as targets in cancer. Br. J. Pharmacol. 2013, 169, 1723–1744. [CrossRef] [PubMed]
135. Dimberg, L.Y.; Anderson, C.K.; Camidge, R.; Behbakht, K.; Thorburn, A.; Ford, H.L. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. *Oncogene* 2013, 32, 1341–1350. [CrossRef]  
136. Thorburn, A.; Behbakht, K.; Ford, H. TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them. *Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother.* 2008, 11, 17–24. [CrossRef] [PubMed]  
137. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. *Cell* 2000, 100, 57–70. [CrossRef]  
138. Hopkins-Donaldson, S.; Bodmer, J.L.; Bourloud, K.B.; Brognara, C.B.; Tschopp, J.; Gross, N. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. *Med. Pediatr. Oncol.* 2000, 35, 608–611. [CrossRef]  
139. Eggert, A.; Grotzer, M.A.; Zuzak, T.J.; Wiewrodt, B.R.; Ho, R.; Ikegaki, N.; Brodeur, G.M. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. *Cancer Res.* 2001, 61, 1314–1319. [PubMed]  
140. Zhang, L.; Zhu, H.; Teraishi, F.; Davis, J.J.; Guo, W.; Fan, Z.; Fang, B. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. *Neoplasia (N. Y.)* 2005, 7, 594–602. [CrossRef]  
141. Lee, S.H.; Shin, M.S.; Kim, H.S.; Lee, H.K.; Park, W.S.; Kim, S.Y.; Lee, J.H.; Han, S.Y.; Park, J.Y.; Oh, R.R.; et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. *Oncogene* 2001, 20, 399–403.  
142. Fisher, M.J.; Virmani, A.K.; Wu, L.; Aplenc, R.; Harper, J.C.; Powell, S.M.; Rebbeck, T.R.; Sidransky, D.; Gazdar, A.F.; El-Deiry, W.S. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 2001, 7, 1688–1697.  
143. Shin, M.S.; Kim, H.S.; Lee, S.H.; Park, W.S.; Kim, S.Y.; Lee, J.H.; Han, S.Y.; Park, J.Y.; Oh, R.R.; et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. *Cancer Res.* 2001, 61, 4942–4946. [PubMed]  
144. Sanlioglu, A.D.; Dirice, E.; Aydin, C.; Erin, N.; Koksoy, S.; Sanlioglu, S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. *BMC Cancer* 2005, 5, 54. [CrossRef]  
145. Neumann, S.; Hasenauer, J.; Pollak, N.; Scheurich, P. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. *J. Biol. Chem.* 2014, 289, 16576–16587. [CrossRef]  
146. O’Leary, L.; van der Sloot, A.M.; Reis, C.R.; Deegan, S.; Ryan, A.E.; Dhami, S.P.; Murillo, L.S.; Cool, R.H.; Correa de Sampaio, P.; Thompson, K.; et al. Decoy receptors block TRAIL sensitivity at a supracellular level: The role of stromal cells in controlling tumour TRAIL sensitivity. *Oncogene* 2016, 35, 1261–1270. [CrossRef]  
147. Trauzold, A.; Siegmund, D.; Schniewind, B.; Sipos, B.; Egberts, J.; Zorenkov, D.; Emme, D.; Rodt, C.; Kalthoff, H.; Wajant, H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. *Oncogene* 2006, 25, 7434–7439. [CrossRef]  
148. Hartwig, T.; Montinaro, A.; von Karstedt, S.; Sevko, A.; Surinova, S.; Chakravarthy, A.; Taraborrelli, L.; Draber, P.; Lafont, E.; Arce Vargas, F.; et al. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. *Mol. Cell* 2017, 65, 730–742.e735. [CrossRef] [PubMed]  
149. Micheau, O. Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation. *Int. J. Mol. Sci.* 2018, 19, 715. [CrossRef]  
150. Dufour, F.; Rattier, T.; Shirley, S.; Picarda, G.; Constantinescu, A.A.; Morle, A.; Zakaria, A.B.; Marcion, G.; Causse, S.; Szegedi, E.; et al. N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death. *Cell Death Differ.* 2017, 24, 500–510. [CrossRef]  
151. Yoshida, T.; Shiraishi, T.; Horinaka, M.; Wakada, M.; Sakai, T. Glycosylation modulates TRAIL-R1/death receptor 4 protein: Different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. *Oncol. Rep.* 2007, 18, 1239–1242. [CrossRef] [PubMed]  
152. Bai, X.; Williams, J.L.; Greenwood, S.L.; Baker, P.N.; Aplin, J.D.; Crocker, J.P. A placental protective role for trophoblast-derived TNF-related apoptosis-inducing ligand (TRAIL). *Placenta* 2009, 30, 855–860. [CrossRef] [PubMed]
153. Bertsch, U.; Röder, C.; Kalthoff, H.; Trauzold, A. Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: Emerging role of nuclear TRAIL-R2. *Cell Death Dis.* 2014, 5, e1390. [CrossRef] [PubMed]

154. Kuang, A.A.; Diehl, G.E.; Zhang, J.; Winoto, A. FADD is required for DR4- and DR5-mediated apoptosis: Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. *J. Biol. Chem.* 2000, 275, 25065–25068. [CrossRef]

155. Zang, F.; Wei, X.; Leng, X.; Yu, M.; Sun, B. C-FLIP (L) contributes to TRAIL resistance in HER2-positive breast cancer. *Biochem. Biophys. Res. Commun.* 2014, 450, 267–273. [CrossRef]

156. Kaminskyy, V.O.; Surova, O.V.; Piskunova, T.; Zborovskaya, I.B.; Tchevkina, E.M.; Andera, L.; Zhivotovsky, B. Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling. *Cell Death Dis.* 2013, 4, e522. [CrossRef] [PubMed]

157. Seol, D.W.; Li, J.; Seol, M.H.; Park, S.Y.; Talanian, R.V.; Billiar, T.R. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Caspase-8 is required for TRAIL-induced apoptosis. *Cancer Res.* 2001, 61, 1138–1143. [PubMed]

158. Tepper, C.G.; Seldin, M.F. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt’s lymphoma. *Blood* 1999, 94, 1727–1737. [PubMed]

159. Olsson, A.; Diaz, T.; Aguilar-Santelises, M.; Osterborg, A.; Celsing, F.; Jondal, M.; Osorio, L.M. Sensitisation to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. *Leukemia* 2001, 15, 1868–1877. [CrossRef] [PubMed]

160. Jeong, M.; Lee, E.W.; Seong, D.; Seo, J.; Kim, J.H.; Grootjans, S.; Kim, S.Y.; Vandenabeele, P.; Song, J. USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability. *Oncogene* 2017, 36, 458–470. [CrossRef]

161. Dolcet, X.; Llobet, D.; Pallares, J.; Rue, M.; Comella, J.X.; Matias-Guiu, X. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. *Lab. Invest.* 2005, 85, 885–894. [CrossRef] [PubMed]

162. Zong, H.; Yin, B.; Chen, J.; Ma, B.; Cai, D.; He, X. Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma. *Tohoku J. Exp. Med.* 2009, 217, 203–208. [CrossRef] [PubMed]

163. Grunert, M.; Gottschalk, K.; Kapahnke, J.; Gündisch, S.; Kieser, A.; Jeremias, I. The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL. *Cell Death Dis.* 2012, 3, e414. [CrossRef] [PubMed]

164. Micheau, O.; Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell* 2003, 114, 181–190. [CrossRef]

165. Bertrand, M.J.; Milutinovic, S.; Dickson, K.M.; Ho, W.C.; Boudreault, A.; Durkin, J.; Gillard, J.W.; Jaquith, J.B.; Morris, S.J.; Barker, P.A. CIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. *Mol. Cell.* 2008, 30, 689–700. [CrossRef] [PubMed]

166. Schneider, P.; Thome, M.; Burns, K.; Bodmer, J.L.; Hofmann, K.; Kataoka, T.; Holler, N.; Tschopp, J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. *Immunity* 1997, 7, 831–836. [CrossRef]

167. Lin, Y.; Devin, A.; Rodriguez, Y.; Liu, Z.G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. *Genes Dev.* 1999, 13, 2514–2526. [CrossRef]

168. Keane, M.M.; Rubinstein, Y.; Cuello, M.; Ettenger, S.A.; Banerjee, P.; Nau, M.M.; Lipkowitz, S. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. *Breast Cancer Res. Treat.* 2000, 64, 211–219. [CrossRef]

169. Trauzold, A.; Wermann, H.; Arlt, A.; Schutze, S.; Schafer, H.; Oestern, S.; Roder, C.; Ungefroren, H.; Lamp, E.; Heinrich, M.; et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. *Oncogene* 2001, 20, 4258–4269. [CrossRef]

170. Khanboloocki, S.; Nawrocki, S.T.; Arumugam, T.; Andtbacka, R.; Pino, M.S.; Kurzrock, R.; Logsdon, C.D.; Abbuzzese, J.L.; McConkey, D.J. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. *Mol. Cancer Ther.* 2006, 5, 2251–2260. [CrossRef]
Cancers 2019, 11, 456

171. Rahighi, S.; Ikeda, F.; Kawasaki, M.; Akutsu, M.; Suzuki, N.; Kato, R.; Kensche, T.; Uejima, T.; Bloor, S.; Komander, D.; et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 2009, 136, 1098–1109. [CrossRef] [PubMed]

172. Zhang, L.; Blackwell, K.; Workman, L.M.; Chen, S.; Pope, M.R.; Janz, S.; Habelhah, H. RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-kappaB Activation and Lymphoma Survival. Mol. Cell. Biol. 2015, 35, 3324–3338. [CrossRef] [PubMed]

173. Tran, S.E.; Holmstrom, T.H.; Ahonen, M.; Kahari, V.M.; Eriksson, J.E. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 2001, 276, 16484–16490. [CrossRef] [PubMed]

174. Zhang, X.D.; Borrow, J.M.; Zhang, X.Y.; Nguyen, T.; Hersey, P. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003, 22, 2869–2881. [CrossRef]

175. Morel, J.; Audo, R.; Hahne, M.; Combe, B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 2005, 280, 15709–15718. [CrossRef] [PubMed]

176. Kandasamy, K.; Srinivasula, S.M.; Alnemri, E.S.; Thompson, C.B.; Korsmeyer, S.J.; Bryant, J.L.; Srivastava, R.K. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: Differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. 2003, 63, 1712–1721. [PubMed]

177. Hinz, S.; Trauzold, A.; Boenicke, L.; Sandberg, C.; Beckmann, S.; Bayer, E.; Walczak, H.; Kalthoff, H.; Ungefor, H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19, 5477–5486. [CrossRef] [PubMed]

178. Fulda, S.; Meyer, E.; Debatin, K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002, 21, 2283–2294. [CrossRef]

179. Zhu, H.; Guo, W.; Zhang, L.; Davis, J.J.; Wu, S.; Teraiishi, F.; Cao, X.; Smythe, W.R.; Fang, B. Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol. Ther. 2005, 4, 393–397. [CrossRef]

180. Vogler, M.; Walczak, H.; Stadel, D.; Haas, T.L.; Genze, F.; Jovanovic, M.; Gschwend, J.E.; Simmet, T.; Debatin, K.M.; Fulda, S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 2008, 68, 7956–7965. [CrossRef]

181. Fakler, M.; Loeder, S.; Vogler, M.; Schneider, K.; Jeremias, I.; Debatin, K.M.; Fulda, S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009, 113, 1710–1722. [CrossRef] [PubMed]

182. Ricci, M.S.; Kim, S.H.; Ogi, K.; Plastaras, J.P.; Ling, J.; Wang, W.; Jin, Z.; Liu, Y.Y.; Dicker, D.T.; Chiao, P.J.; et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007, 12, 66–80. [CrossRef]

183. Zhang, X.D.; Zhang, X.Y.; Gray, C.P.; Nguyen, T.; Hersey, P. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance. J. Biol. Chem. 2003, 278, 2685–2694. [CrossRef]

184. Duckett, C.S.; Nava, V.E.; Gedrich, R.W.; Clem, R.J.; Van Dongen, J.L.; Gilfillan, M.C.; Shiels, H.; Hardwick, J.M.; Thompson, C.B. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 1996, 15, 2685–2694. [CrossRef]

185. Ng, C.P.; Zisman, A.; Bonavida, B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance. Prostate 2002, 53, 286–299. [CrossRef] [PubMed]

186. Ng, C.P.; Bonavida, B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: Sensitisation by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol. Cancer Ther. 2002, 1, 1051–1058. [CrossRef] [PubMed]

187. Alleniworth, J.L.; Aird, K.M.; Aldrich, A.J.; Batinic-Haberle, I.; Devi, G.R. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol. Cancer Ther. 2012, 11, 1518–1527. [CrossRef] [PubMed]

188. Sommer, K.W.; Schamberger, C.J.; Schmidt, G.E.; Sasgary, S.; Cerni, C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2003, 22, 4266–4280. [CrossRef]
189. Holcik, M.; Yeh, C.; Korneluk, R.G.; Chow, T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. *Oncogene* 2000, 19, 4174–4177. [CrossRef] [PubMed]

190. Nagata, M.; Nakayama, H.; Tanaka, T.; Yoshida, R.; Yoshitake, Y.; Fukuda, M.; Kawahara, K.; Nakašawa, Y.; Ota, K.; Hiraki, A.; et al. Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma. *Br. J. Cancer* 2011, 105, 1322–1330. [CrossRef]

191. Silke, J.; Meier, P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. *Cold Spring Harb. Perspect. Biol.* 2013, 5, a008730. [CrossRef] [PubMed]

192. Fulda, S. Smac Mimetics to Therapeutically Target IAP Proteins in Cancer. *Int. Rev. Cell Mol. Biol.* 2017, 330, 157–169.

193. Galluzzi, L.; Baehrecke, E.H.; Ballabio, A.; Boya, P.; Bravo-San Pedro, J.M.; Ceconi, F.; Choi, A.M.; Chu, C.T.; Codogno, P.; Colombo, M.I.; et al. Molecular definitions of autophagy and related processes. *EMBO J.* 2017, 36, 1811–1836. [CrossRef] [PubMed]

194. Klionsky, D.J. Autophagy: From phenomenology to molecular understanding in less than a decade. *Nat. Rev. Mol. Cell Biol.* 2007, 8, 931–937. [CrossRef]

195. Mizushima, N.; Klionsky, D.J. Protein turnover via autophagy: Implications for metabolism. *Annu. Rev. Nutr.* 2007, 27, 19–40. [CrossRef] [PubMed]

196. Denton, D.; Kumar, S. Autophagy-dependent cell death. *Cell Death Differ.* 2019, 26, 605–616. [CrossRef] [PubMed]

197. Mihaylova, M.M.; Shaw, R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. *Nat. Cell Biol.* 2011, 13, 1016. [CrossRef]

198. Rabinowitz, J.D.; White, E. Autophagy and p53. *Cold Spring Harb. Perspect. Med.* 2016, 6, a026120. [CrossRef]

199. Liang, X.H.; Jackson, S.; Seaman, M.; Brown, K.; Kempkes, B.; Hibshoosh, H.; Levine, B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature* 1999, 402, 672–676. [CrossRef]

200. Pentimalli, F. Autophagy in disease: Hunger for translation. *Cell Death Dis.* 2019, 10, 247. [CrossRef] [PubMed]

201. Mills, K.R.; Reginato, M.; Debnath, J.; Queenan, B.; Brugge, J.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. *Proc. Natl. Acad. Sci. USA* 2004, 101, 3438–3443. [CrossRef]

202. Das, S.; Nayak, A.; Siddharth, S.; Nayak, D.; Narayan, S.; Kundu, C.N. TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions. *Cell. Oncol.* 2017, 40, 593–607. [CrossRef] [PubMed]

203. Sakamaki, J.I.; Ryan, K.M. Autophagy Determines the Path on the TRAIL to Death. *Dev. Cell* 2016, 37, 291–293. [CrossRef]

204. He, W.; Wang, Q.; Xu, J.; Xu, X.; Padilla, M.T.; Ren, G.; Gou, X.; Lin, Y. Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/ RIP1-mediated MAPK8/JNK activation. *Autophagy* 2012, 8, 1811–1821. [CrossRef] [PubMed]
11. Herrero-Martin, G.; Hoyer-Hansen, M.; Garcia-Garcia, C.; Fumarola, C.; Farkas, T.; Lopez-Rivas, A.; Jaatela, M. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. *EMBO J.* 2009, 28, 677–685. [CrossRef] [PubMed]

12. Han, J.; Hou, W.; Goldstein, L.A.; Stolz, D.B.; Watkins, S.C.; Rabinovich, H. A Complex between Atg7 and Caspase-9: A Novel Mechanism of Cross-regulation between Autophagy and Apoptosis. *J. Biol. Chem.* 2014, 289, 6485–6497. [CrossRef]

13. Nakano, K.; Vousden, K.H. PUMA, a novel proapoptotic gene, is induced by p53. *Mol. Cell* 2001, 7, 683–694. [CrossRef]

14. Thorburn, J.; Andrysik, Z.; Staskiewicz, L.; Gump, J.; Maycotte, P.; Oberst, A.; Green, D.R.; Espinosa, J.M.; Thorburn, A. Autophagy controls the kinetics and extent of mitochondrial apoptosis by regulating PUMA levels. *Cell Rep.* 2014, 7, 45–52. [CrossRef]

15. Pouyssegur, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 2006, 441, 437–443. [CrossRef]

16. Knoll, G.; Bittner, S.; Kurz, M.; Jantsch, J.; Ehrenschwender, M. Hypoxia regulates TRAIL sensitivity of colorectal cancer cells through mitochondrial autophagy. *Oncotarget* 2016, 7, 41488–41504. [CrossRef]

17. Di, X.; Zhang, G.; Zhang, Y.; Takeda, K.; Rivera Rosado, L.A.; Zhang, B. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. *Oncotarget* 2013, 4, 1349–1364. [CrossRef]

18. Twomey, J.D.; Zhang, B. Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model. *Cancers* 2019, 11, 94. [CrossRef] [PubMed]

19. Roux, J.; Hafner, M.; Bandara, S.; Sims, J.J.; Hudson, H.; Chai, D.; Sorger, P.K. Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold. *Mol. Syst. Biol.* 2015, 11, 803. [CrossRef]

20. Spencer, S.L.; Gaudet, S.; Albeck, J.G.; Burke, J.M.; Sorger, P.K. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. *Nature* 2009, 459, 428–432. [CrossRef]

21. Tang, W.; Wang, W.; Zhang, Y.; Liu, S.; Liu, Y.; Zheng, D. TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner. *Cell Res.* 2009, 19, 758–767. [CrossRef]

22. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* 2011, 144, 646–674. [CrossRef] [PubMed]

23. Kischkel, F.C.; Lawrence, D.A.; Chunthurapai, A.; Schow, P.; Kim, K.J.; Ashkenazi, A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. *Immunity* 2000, 12, 611–620. [CrossRef]

24. Hymowitz, S.G.; O’Connell, M.P.; Ultsch, M.H.; Hurst, A.; Totpal, K.; Ashkenazi, A.; de Vos, A.M.; Kelley, R.F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. *Biochemistry* 2000, 39, 633–640. [CrossRef] [PubMed]

25. Bodmer, J.L.; Meier, P.; Tschopp, J.; Schneider, P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. *J. Biol. Chem.* 2000, 275, 20632–20637. [CrossRef]

26. Lawrence, D.; Shahrokh, Z.; Marsters, S.; Achilles, K.; Shih, D.; Mounho, B.; Hillan, K.; Totpal, K.; DeForge, L.; Schow, P.; et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. *Nat. Med.* 2001, 7, 383–385. [CrossRef] [PubMed]

27. Jo, M.; Kim, T.H.; Seol, D.W.; Esplen, J.E.; Dorko, K.; Billiar, T.R.; Strom, S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. *Nat. Med.* 2000, 6, 564–567. [CrossRef] [PubMed]

28. Nagata, S. Steering anti-cancer drugs away from the TRAIL. *Nat. Med.* 2000, 6, 502–503. [CrossRef]

29. Lemke, J.; von Karstedt, S.; Abd El Hay, M.; Conti, A.; Arce, F.; Montinaro, A.; Papenfuss, K.; El-Bahrawy, M.A.; Walczak, H. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. *Cell Death Differ.* 2014, 21, 491–502. [CrossRef] [PubMed]

30. Haynes, N.M.; Hawkins, E.D.; Li, M.; McLaughlin, N.M.; Hammerling, G.J.; Schwendener, R.; Winoto, A.; Wensky, A.; Yagita, H.; Takeda, K.; et al. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. *J. Immunol.* 2010, 185, 532–541. [CrossRef]

31. Holland, P.M. Death receptor agonist therapies for cancer, which is the right TRAIL? *Cytokine Growth Factor Rev.* 2014, 25, 185–193. [CrossRef]
234. Tuthill, M.H.; Montinaro, A.; Zinngrebe, J.; Prieske, K.; Draber, P.; Prieske, S.; Newsom-Davis, T.; von Karstedt, S.; Graves, J.; Walczak, H. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. *Oncogene* 2015, 34, 2138–2144. [CrossRef]  
235. Leidl, K.; Hauser, C.; Egberts, J.H.; Willms, A.; Henweer, C.; Boreitius, S.; Röcken, C.; Glüer, C.-C.; Becker, T.; Kluge, M.; et al. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. *Cell Death Dis.* 2018, 9, 445. [CrossRef]  
236. Hari, Y.; Harashima, N.; Tajima, Y.; Harada, M. Bel-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL. *Oncotarget* 2015, 6, 41902–41915. [CrossRef] [PubMed]  
237. Noonan, A.M.; Bunch, K.P.; Chen, J.Q.; Herrmann, M.A.; Lee, J.M.; Kohn, E.C.; O’Sullivan, C.C.; Jordan, E.; Houston, N.; Takebe, N.; et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. *Cancer* 2016, 122, 588–597. [CrossRef] [PubMed]  
238. Niemoeller, O.M.; Belka, C. Radiotherapy and TRAIL for cancer therapy. *Cancer Lett.* 2013, 332, 184–193. [CrossRef] [PubMed]  
239. Einsele, H. Bortezomib. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. *Am. J. Dis. Child.* 2014, 201, 325–345.  
240. Bychkov, M.L.; Gasparian, M.E.; Dolgikh, D.A.; Kirpichnikov, M.P. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4. *PLoS ONE* 2014, 9, e109756. [CrossRef] [PubMed]  
241. Legler, K.; Hauser, C.; Egberts, J.-H.; Willms, A.; Heneweer, C.; Boretius, S.; Röcken, C.; Glüer, C.-C.; Becker, T.; von Karstedt, S.; Graves, J.; Walczak, H. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. *Oncogene* 2015, 34, 2138–2144. [CrossRef]  
242. Chen, Y.; Zhou, X.; Qiao, J.; Bao, A. Autophagy is a regulator of TRAIL-induced apoptosis in NSCLC A549 cells. *J. Cell Commun. Signal.* 2017, 11, 219–226. [CrossRef] [PubMed]  
243. Kao, C.; Chao, A.; Tsai, C.L.; Chuang, W.C.; Huang, W.P.; Chen, G.C.; Lin, C.Y.; Wang, T.H.; Wang, H.S.; Lai, C.H. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. *Cell Death Dis.* 2014, 5, e1510. [CrossRef] [PubMed]  
244. Martinez-Lopez, N.; Athonvarangkul, D.; Mishall, P.; Sahu, S.; Singh, R. Autophagy proteins regulate ERK phosphorylation. *Nat. Commun.* 2013, 4, 2799. [CrossRef] [PubMed]  
245. Geserick, P.; Drewniok, C.; Hupe, M.; Haas, T.L.; Diessenbacher, P.; Sprick, M.R.; Schon, M.P.; Henkler, F.; Gollnick, H.; Walczak, H.; et al. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. *Oncogene* 2008, 27, 3211–3220. [CrossRef] [PubMed]  
246. Wu, Y.; Giasis, M.; Kohler, R.; Chen, W.M.; Krammer, P.H.; Li-Weber, M. Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenograft model. *Cancer Lett.* 2017, 389, 70–77. [CrossRef] [PubMed]  
247. Li-Weber, M. Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines). *Int. J. Cancer* 2015, 137, 1791–1799. [CrossRef] [PubMed]  
248. Nalli, A.D.; Brown, L.E.; Thomas, C.L.; Sayers, T.J.; Porco, J.A., Jr.; Henrich, C.J. Sensitisation of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs. *Sci. Rep.* 2018, 8, 17519. [CrossRef]  
249. Luan, Z.; He, Y.; He, F.; Chen, Z. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. *Mol. Med. Rep.* 2015, 11, 203–211. [CrossRef]  
250. Fulda, S. Molecular pathways: Targeting inhibitor of apoptosis proteins in cancer— from molecular mechanism to therapeutic application. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 2014, 20, 289–295. [CrossRef]  
251. Fulda, S.; Wick, W.; Weller, M.; Debatin, K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. *Nat. Med.* 2002, 8, 808–815. [CrossRef] [PubMed]  
252. Li, L.; Thomas, R.M.; Suzuki, H.; De Brabander, J.K.; Wang, X.; Harran, P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. *Science (N. Y.)* 2004, 305, 1471–1474. [CrossRef]  
253. Noonan, A.M.; Bunch, K.P.; Chen, J.Q.; Herrmann, M.A.; Lee, J.M.; Kohn, E.C.; O’Sullivan, C.C.; Jordan, E.; Houston, N.; Takebe, N.; et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. *Cancer* 2016, 122, 588–597. [CrossRef] [PubMed]
254. Schilder, R.J.; Albertella, M.; Strauss, J.; Sydvander, M.; Nair, S.M.; Urakpo, K.; Norin, S.; Öhd, J. A phase 1/2 study with birinapant in combination with pembrolizumab. *J. Clin. Oncol.* 2018, 36 (Suppl. 15), TPS3131. [CrossRef]

255. Hamilton, E.P.; Birrer, M.J.; DiCarlo, B.A.; Gaillard, S.; Martin, L.P.; Nemunaitis, J.J.; Perez, R.P.; Schilder, R.J.; Annunziata, C.M.; Begley, C.G.; et al. A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. *J. Clin. Oncol.* 2015, 33 (Suppl. 15), 5571. [CrossRef]

256. Delbridge, A.R.; Strasser, A. The BCL-2 protein family, BH3-mimetics and cancer therapy. *Cell Death Differ.* 2015, 22, 1071–1080. [CrossRef]

257. Kumar, S.; Kaufman, J.L.; Gasparetto, C.; Mikhail, J.; Vij, R.; Pegourie, B.; Benboubker, L.; Facon, T.; Amiot, M.; Moreau, P.; et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. *Blood* 2017, 130, 2401–2409. [CrossRef] [PubMed]

258. Stilgenbauer, S.; Eichhorst, B.; Schetelig, J.; Coutre, S.; Seymour, J.F.; Munir, T.; Puvvada, S.D.; Wendtner, C.M.; Roberts, A.W.; Jurczak, W.; et al. Venetoclax in relapsed or refractory chronic lymphocytic leukemia with 17p deletion: A multicentre, open-label, phase 2 study. *Lancet Oncol.* 2016, 17, 768–778. [CrossRef]

259. Jones, J.A.; Mato, A.R.; Wierda, W.G.; Davids, M.S.; Choi, M.; Cheson, B.D.; Furman, R.R.; Lamanna, N.; Barr, P.M.; Zhou, L.; et al. Venetoclax for chronic lymphocytic leukemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2018, 19, 65–75. [CrossRef]

260. Tolcher, A.W.; LoRusso, P.; Arzt, J.; Busman, T.A.; Lian, G.; Rudersdorf, N.S.; Vanderwal, C.A.; Kirschbrown, W.; Holen, K.D.; Rosen, L.S. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. *Cancer Chemother. Pharmacol.* 2015, 76, 1025–1032. [CrossRef]

261. Yang, J.; Pradhan, R.S.; Rosen, L.S.; Graham, A.M.; Holen, K.D.; Xiong, H. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer. *J. Clin. Pharm. Ther.* 2014, 39, 680–684. [CrossRef] [PubMed]

262. Gentile, M.; Petrungaro, A.; Uccello, G.; Vigna, E.; Recchia, A.G.; Caruso, N.; Bossio, S.; De Stefano, L.; Palumbo, A.; Storino, F.; et al. Venetoclax for the treatment of chronic lymphocytic leukemia. *Expert Opin. Investig. Drugs* 2017, 26, 1307–1316. [CrossRef]

263. Huang, S.; Sinicrope, F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. *Cancer Res.* 2008, 68, 2944–2951. [CrossRef] [PubMed]

264. Wang, G.; Zhan, Y.; Wang, H.; Li, W. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. *Cancer Chemother. Pharmacol.* 2012, 69, 799–805. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).